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Abstract
JOY ELIZABETH KIRKPATRICK. Validation and Development of KDM4B Inhibitors to
Target Periodontal Disease Progression. (Under the direction of PATRICK WOSTER).
Periodontal disease (PD) affects nearly half of the adult United States population and is
characterized by bacterial-driven inflammatory bone loss. Traditional and emerging
treatments for periodontitis management do not typically target the host immune response,
which is the major source of tissue damage. The demethylation activity of lysine-specific
demethylase 1 (KDM1A) at histone 3 lysine 4 leads to a decrease in pro-inflammatory
cytokine transcription. By contrast, lysine specific demethylase 4B (KDM4B) is a histone
demethylase that specifically demethylates histone 3 trimethyllysine 9 (H3K9me3).
Interestingly, previous data has shown that cross talk between these two enzymes leads
to a balanced system wherein lysine 9 methylation serves as a prerequisite to lysine 4
demethylation by KDM1A. The studies outlined in this dissertation will exploit this crosstalk
for the design of new potential therapies for PD. The central hypothesis of this dissertation
is that promotion of KDM1A activity by introduction of a specific KDM4B inhibitor will
alleviate PD by controlling the overactive immune system in diseased areas, enabling the
host to better manage the disease. This hypothesis was tested through completion of the
following Specific Aims: Specific Aim 1: To mechanistically define the role of KDM4B in
periodontal inflammation; Specific Aim 2: To design a novel inhibitor of KDM4B for
adjunctive treatment of PD inflammation, and Specific Aim 3: To evaluate novel and known
KDM4B inhibitors for in vivo activity as anti-inflammatory agents. KDM4B inhibition
prevented the A.a-induced immune response in vitro and in vivo. KDM4B inhibition also
reduced osteoclast formation in vitro and bone loss in vivo. KDM4B activity is heightened
in periodontal disease in clinical tissues as well as in murine calvarial tissue sections
treated with A.a. KDM4B inhibition mediated immunosuppression relies on the concurrent
overactivation of KDM1A. Computational chemical screens identified several hit scaffolds,
one of which was optimized using phenotypic screen guided binary QSAR. From an
extensive in silico derivative library, 25 novel derivatives were synthesized, 8 of which
caused significant immunosuppression.

xii

Chapter 1: Background and Significance

1.1. Periodontal Disease
1.1.a. Clinical Significance and Epidemiology
Periodontitis is a chronic oral inflammatory condition that destroys the supporting
tissues of teeth, resulting in irreversible damage including bone loss and tooth loss.
Currently, this disease affects 42% of dentate adults in the United States. There is higher
prevalence of the disease associated with adults 65 years or older, Mexican-Americans,
non-Hispanic blacks and smokers.1 Severe periodontal disease is estimated by the world
health organization to be the 11th most prevalent disease globally.2 Although traditional
therapies performed by clinicians are effective for a large proportion of patients, these
measures come at a cost, with 20% of out-of-pocket health expenditure coming from
dental treatment.3 This is largely due to a derisory ability to control the disease which is
a direct result of our inadequate understanding of the underlying disease
pathophysiology.
1.1.b. Clinical Diagnosis
While a consensus for diagnosis of specific periodontal diseases has been difficult
to achieve due to the complexity of the disease,4 the American Academy of Periodontology
suggests that a diagnosis can be reached by a combination of clinical measurements.
These measurements seek to identify the extent of inflammatory involvement by
measuring probing depth, clinical attachment loss (CAL) and bleeding on probing (BOP)
combined with the extent of alveolar bone loss which can be measured radiographically.5
Probing depth is measured by inserting a periodontal probe into the gingival sulcus in
2

health or periodontal pocket in disease while applying light pressure. Probing depth
measures the linear distance from the base of the sulcus or pocket to the gingival margin,
where a measurement of < 4 mm is considered healthy. Clinical attachment loss measures
the linear distance from the depth of the sulcus or pocket to the cementoenamel junction
(CEJ), which may be more accurate as it eliminates variability in clinical crown size,
accounting for differences in gingival recession and excess between patients. While
extensive literature supports clinical attachment loss as the most important measurement
in diagnosis of periodontal disease, this is commonly not measured clinically, and while
inferior, probing depth is taken in its place.6-7 Nevertheless, increases in these measures
demonstrate that there has already been apical migration of the connective tissue
attachment of the periodontal ligament, which connects the cementum of the tooth to
bone. When the force of tension from the periodontal ligament onto the bone is lost, the
bone remodels and there is a net loss of bone in the area,8 which can be seen
radiographically. In a complementary process, inflammatory mediators associated with
periodontal lesions activate bone resorbing osteoclasts. This combination of events can
lead to drastic levels of bone loss, which can involve the furcation, result in severe
fremitus, or result in the ultimate extreme: tooth loss.
In addition to taking linear measurements to assess alveolar bone loss, soft tissues
are assessed for bleeding. In an intact gingival sulcus of a healthy patient, junctional
epithelium serves to protect the underlying connective tissue from exposure to the oral
environment. Unlike other types of epithelium, junctional epithelium contains relatively few
desmosomes and occasionally has gap junctions.9 Inter-cellular spacing is also much
higher even when compared to the adjacent sulcular or gingival epithelium. Lastly, while
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the junctional epithelium has something that resembles a basement membrane, it is
structurally unique, lacking several major components such as collagen IV and VII.
Therefore, the normal physical barrier contained within most types of epithelium is not
existent in the junctional epithelium.10 Because of this, immune cells such as
polymorphonuclear leukocytes (neutrophils), macrophages, lymphocytes and dendritic
cells can continuously sample the environment and respond to an overwhelming insult.
When the inflammatory cells are chronically activated, such as is seen in the presence of
specific so-called “perio-pathogens” or in the presence of a large mass of plaque or
calculus, the periodontal ligament collagen fibers detach from the root cementum of the
tooth, resulting in transformation of the junctional epithelium to long junctional epithelium.
At this point, the healthy gingival sulcus has fully transformed into a periodontal pocket,
where overgrowth and leakiness of blood vessels is a common occurrence.11 In the case
that there is any bleeding at all, this is considered unhealthy and is recorded in the patient’s
chart. Lastly, plaque index is a measure of the patient’s current plaque load, which has
been established with little debate as the initial causative agent of periodontal disease.
Overall, clinical measurements to diagnose periodontal disease aim to evaluate three
main factors: oral hygiene, inflammation and bone loss.
According to the 1999 consensus report on periodontal classifications,12
periodontal disease is classified based on whether it is chronic or aggressive, and again
by whether it is generalized or localized.13 Aggressive periodontitis presents in patients
who are otherwise healthy, but exhibit rapid bone and attachment loss. This is thought to
be attributed to an underlying genetic predisposition, as it is seen in families. 14 Although
not universally present, patients generally have elevated levels of A.a in their biofilms, and
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have a disproportionate immune response to the amount of plaque present with hyperresponsive macrophages.15 In chronic periodontitis, the amount of bone and attachment
loss directly correlates with the plaque load and subgingival calculus is commonly present.
This form of disease can be associated with other systemic diseases and has a slow rate
of progression, According to this classification system, both forms of disease can either
be localized, where ≤ 30% of total sites are diseased, or generalized, where >30% of sites
are diseased. While this classification system proved useful to clinicians and researchers
for several years, it did not address the complexity and confounding variables within
periodontal diseases, nor did it have a valid justification for differentiating between chronic
and aggressive periodontal disease.
In 2018, a new international classification system for periodontal disease was
developed following the 2017 World Workshop on the Classification of Periodontal and
Peri‐Implant Diseases and Conditions.16 This current classification system groups chronic
and aggressive periodontitis under one category of disease (periodontitis) and has only
two additional disease classifications that can be considered periodontal disease:
periodontitis as a direct manifestation of systemic disease, and necrotizing periodontitis.
Within periodontitis, disease is further defined by stages I through IV, and grades A, B,
and C. Stages increase based on severity, complexity and extent and distribution of
disease, and grades increase based on both direct and indirect evidence of progression
as well as risk factors. Necrotizing periodontal disease is periodontal disease where there
is necrosis of the papilla, bleeding and pain and is classified into two categories based on
the affected patient population: chronically, severely compromised patients and
temporarily or moderately compromised patients. Periodontitis as a direct manifestation
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of systemic disease is diagnosed by identification of a rare host immune modulating
systemic disease. In the absence of a rare systemic disease or necrotizing lesion, where
there is an interdental CAL at ≥ 2 non-adjacent teeth or CAL of ≥ 3mm at ≥2 teeth, the
disease is considered periodontitis and should be staged and graded according to its
characteristics. In addition to these three main forms of periodontal disease, additional
separate diagnoses exist for periodontal abscesses as well as endo-periodontal lesions.
In a periodontal abscess, there is localized accumulation of pus within the periodontal
pocket. In endo-periodontal lesions, there is a pathologic communication between
periodontal and pulpal tissues where either one causes the other or they occur
simultaneously.16 While the clinical diagnosis of aggressive periodontitis has been
eliminated, the characteristic presentation can be alternatively described as Stage III.C
with a molar incisor pattern.16 Periodontal disease classification has undergone many
changes over the years and will continue to evolve as more information is discovered.
1.1.c. Pathogenesis: Introduction
The specific pathway that leads to initiation and progression of periodontal disease
has been debated for decades. In the 1970s, several groups had committed to the “codestructive factor” hypothesis,17 suggesting that traumatic occlusion or other mild injuries
adjacent to plaque and calculus was enough to initiate destruction of periodontal tissues.1819

By 1980, the critical importance of the exaggerated immune response in the etiology of

periodontal destruction had been established. The co-destructive factor hypothesis was
disproved; removing the source of trauma in the presence of inflammation had no effect
on bone regeneration or connective tissue attachment, while resolution of inflammation in
the presence of trauma produced this effect.20-23 These data suggested there was rather
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a “continuous disease” hypothesis, where the disease would progress continuously until
intervention or tooth loss. Unfortunately, inflammation is a very complex process, and the
periodontium is a very complex site, and newer studies were suggesting that periodontal
disease was a dynamic, multi-factorial process that wasn’t continuous or predictable.24-25
In 1984, Socransky et. al suggested a systemic factor for the progression of periodontal
disease for the first time, pointing to a correlation of periodontally destructive events with
specific life events such as pregnancy. This breakthrough study also fed into the
conversation regarding different forms of periodontal disease, and the importance in
distinguishing between them for accuracy of further research.26
What has remained constant over the years is the importance of plaque and
calculus for the initiation of periodontal disease. The development of calculus generally
progresses through three distinct phases: pellicle formation, plaque development and
calcification. The pellicle is a thin biofilm layer of mainly protein that forms on teeth
naturally throughout the day. Plaque on the other hand, is a microenvironment that
contains living microorganisms such as bacteria, viruses and fungi as well as an
extracellular matrix of salivary proteins and food particles.27 This microenvironment has
the potential to undergo specific changes which confer benefits to the survival of more
pathogenic bacteria.28 For periodontal disease, potential for true detriment depends
primarily on the third stage, calcification. Calcium salts from saliva and dietary sources
can incorporate into the intricate plaque lattice and form a mineralized and tightly adhered
mass to the tooth structure. This allows for adherence of new biofilm upon its surface,
leading to a host tissue response in the form of immune activation as well as detachment
from the tooth to move away from the growing mass.27 Additionally, calculus can bar off
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viable microbial environments from things that might otherwise keep them at bay.29
Calculus is tightly adhered to the tooth structure, requiring professional removal by
clinicians using either scalers or ultrasonic cleaners. Because of this well-defined
progression of events centered on biofilms, it is of critical importance to educate patients
on at home and in office oral hygiene measures. The use of soft-bristled toothbrushes,
floss and regular dental visits may have the potential to prevent most cases of periodontal
disease.
1.1.d. Pathogenesis: Inflammation
Unfortunately for some patients, the discussion of prevention is too little too late,
and calculus has been present long enough to elicit an immune response. The human
body has two main pathways by which it fights off damaging insults: innate and adaptive
immunity. Innate immunity innate immune cells such as macrophages and neutrophils
detect evolutionarily conserved molecular patterns shared by all pathogens and mount a
non-specific immune response.30 On the other hand, adaptive immune cells such as T and
B lymphocytes have receptors specific to a single pathogen and mount a memory-based
immune response.30 Periodontal disease develops through activation of both innate and
adaptive immunity. The focus of this dissertation is on the innate immune response, and
more specifically on macrophages, which have the capability to phagocytose pathogens
process their antigens and signal to other immune cells through antigen presentation as
well as secretion of cytokines and chemokines.30 When calculus is present on the surface
of the tooth, macrophages that continually sample their environment commonly find
danger associated molecular patterns (DAMPs) that are secreted by damaged or dying
vascular and epithelial cells.31-32 On the other hand, the pathogenic gram-negative
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bacteria housed by the calculus mass have lipopolysaccharide (LPS) on their cell surface
which is made pathogenic by the carbohydrate or O-antigen portion of its structure. LPS
can act as a pathogen associated molecular pattern (PAMP) and directly activate
macrophages through binding to a specific pattern recognition receptor (PRR) on their cell
surface. These receptors are called Toll-like receptors (TLR) and of the 11 classes found
in humans, TLR-4 is specifically activated by periopathogenic LPS.
Activation of these TLRs results in signaling through the cell in a well-studied
inflammatory cascade. This signaling ultimately results in activation of nuclear factor
kappa beta (NF-κB), a transcription factor responsible for creation of inflammatory
cytokines such as IL-1β, IL-6 and TNF-α. First, TLR-4 activation is initiated through
homodimerization following complex assembly with LPS, CD14 as a co-receptor, MD-2
as an adapter, and LPS-binding protein as a cofactor.33 Following successful binding of
LPS, TLR-4 signals to either myeloid differentiation factor 88 (MyD88) or toll/interferon
receptor domain containing adapter-inducing interferon B (TRIF) and these are named
the MyD88 dependent and independent pathways, respectively.34 In the MyD88
dependent pathway, another split in the pathway occurs where either IκB kinase (IKK)
activates NF-κb or mitogen-activated protein kinases (MAPKs) activate activating protein
1 (AP-1). Both NF-κb and AP-1 are transcription factors that produce IL-6, IL-1b and TNFa. In the MyD88 independent pathway, IFN-β is produced through activation of Interferon
Regulatory Factor-3 (IRF-3) via TRAF-family-member-associated NF-κB activator
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(TANK)-binding kinase 1 and IKKs.35 Several of these cytokines can reliably be found in
the gingival crevicular fluid of periodontally diseased hosts,36 and the use of these
cytokines as a biomarker has been under investigation for several decades.37 These pro-

Figure 1.1. Inflammatory cascade initiated by bacterial lipopolysaccharide resulting in production of proinflammatory cytokines.

inflammatory cytokines initiate signaling cascades to attempt to re-establish periodontal
homeostasis.38 Unfortunately, calculus is a fortified mass that is largely impenetrable by
these forces while the host tissues, on the other hand, are highly susceptible to damage.
In a perfect world, the immune response would be able to clear the calculus and spare
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the host of any damage. In reality, the opposite happens: host tissues suffer while the
calculus and bacteria it houses thrive even more. (Figure 1.1)
Interestingly, macrophages play a dual role in periodontal disease depending on
how polarized they are towards inflammation or resolution. Classically activated or M1
macrophages can secrete pro-inflammatory cytokines to recruit additional immune cells
to the site. These macrophages are activated by exposure to lipopolysaccharide or IFNγ. On the other hand, pro-resolving macrophages or M2 macrophages have more antiinflammatory capabilities.39 M2 macrophages can be further broken down into M2a, M2b,
or M2c depending on their specific activating factors.40 In periodontal disease, there is an
imbalance in the M1/M2 ratio, where M1 macrophages predominate for the purpose of
clearing microbes. This imbalance leads to tissue destruction characteristic of periodontal
disease.41 Many studies have been conducted to understand the dynamics that govern
polarization of macrophages towards one subset or another, as tight control of these
processes could prove useful therapeutically. For example, KDM4D knockdown in
fibroblasts results in IL-12 gene repression.42 IL-12 is associated with M1/Th1 immunity,
as opposed to IL-10 which would drive the immune system towards M2/Th2 immunity.43
Additionally, JMJD3 has been shown to be induced by LPS stimulation in macrophages.44
This epigenetic enzyme demethylates H3K27me3 to H3K27me and its activity is critical
for macrophage polarization into the M2 or anti-inflammatory state.45

The

KDM4B/KDM1A axis is likely involved in this process heavily, as previous literature has
shown that inhibition of the KDM4 family induces apoptosis in M1 macrophages and
conversely introduction of a KDM1A inhibitor promotes expression of M1 markers and
decreases M2 markers.46-47
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In addition to
macrophages,
there are several
other

important

immune cells that
play a key role in
progression

of

periodontal

Figure 1.2. Summary of immune cells involved in periodontal disease pathogenesis.

disease. (Figure
1.2) Although it is
impossible

to

detail every cell
involved

in

addition to all of
their

diverse

functions, a brief
overview will be
provided. Gingival
epithelial cells are
a primary barrier
to

bacterial

invasion as they
line

the

connective tissue where periodontal inflammatory destruction is initiated and therefore
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provide a mechanical barrier. Neutrophils, also known as polymorphonuclear cells or
PMNs, are a hallmark of acute inflammation.48 They are recruited by IL-8, which is
secreted by junctional epithelial cells following injury.49 Neutrophils secrete granules that
are generally protective but when aberrantly released can cause tissue and extracellular
matrix damage. Additionally, neutrophils are short lived and the accumulation of dead cells
in the periodontal tissues leads to additional tissue damage.50 Dendritic cells (DCs) are
professional antigen presenting cells that survey their environment and have the most
potent T cell activating function of all cells in the body.51 Thus, DCs are a major connecting
point between innate and adaptive immunity and have been shown to affect periodontal
disease pathogenesis positively and negatively.52 In fact, dendritic cells can differentiate
into bone-resorbing osteoclasts, causing bone loss directly.53 Additionally, adaptive
immunity plays a role in periodontal disease pathogenesis. CD4+ T cells, also known as
T helper cells, play a central role in immunity and have several subsets. For example, Th1
and Th17 cells are pro-inflammatory and are directed toward intracellular pathogens and
bacteria, respectively.54 Both of these cell types are positively correlated with chronic
periodontitis in humans,55 and inhibition of differentiation of either cell type confers
protection from destruction.56-57 Th17 cells are upregulated in response to microbial
dysbiosis56 as well as mechanical damage,55 both of which have been thought to
contribute to pathogenesis of PD. B cells, which produce antibodies, are another adaptive
immune cell type involved in PD pathogenesis. While B cells produce antibodies to
bacterial antigens, they are also able to promote destruction of host tissues through
production of anti-self antibodies.58 In fact, B cell deficient mice do not develop bone loss
following bacterial infection, suggesting a pathologic role of these cells likely through
stimulation of osteoclasts and other immune cells.59 While many other immune cells play
13

a role such as natural killer cells,60 endothelial cells,61 fibroblasts,62 myeloid derived
suppressor cells63 and more, it is increasingly clear that pathogenesis of periodontal
disease is a complex process that is difficult to accurately model by using a single cell type
and this will continue to challenge the field for some time.
1.1.e. Pathogenesis: Bacteria
In 1998 Socransky et. al. proposed that there are five main complexes of bacterial
species that colonize periodontally diseased sites.64 This study implicated the “red
complex” of bacteria as being highly correlated to deep pocket depths and bleeding on
probing.64 These pathogens include: Porphyromonas gingivalis, Treponema denticola,
and Tannerella forsythia.64 More recently, Hajishengallis et. al. proposed the “keystone
pathogen hypothesis” which suggests that single, lowly abundant microorganisms lead
to a dysbiotic periodontal microenvironment.65 This study suggested that Porphyromonas
gingivalis was a keystone pathogen that if targeted individually, could result in resolution
of inflammatory periodontal damage by stabilizing the dysbiotic microbial community.65
More recently it was discovered that this model was oversimplified, and periodontal
disease was dependent on a complex process leading to dysbiosis and altered overall
subgingival flora rather than the mere presence of one or more specific periopathogens.66
This model, termed the polymicrobial synergy and dysbiosis (PSD) model, considers that
the polymicrobial biofilm is interdependent and pathogenic as a system rather than singly
dependent on a keystone or red complex pathogen.66 Further studies have identified
individual species related to specific disease subsets, such as Aggregatibacter
actinomycetemcomitans (A.a), which has been uniquely associated with aggressive and
highly destructive forms of PD.67 While we have not yet been able to successfully use
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the presence of specific pathogens as a screening device for progressive versus nonprogressive lesions or for classification of periodontal diseases,15 we have used this
information to enhance our understanding of the biologic mechanisms at play and
augment our in vitro and in vivo experimental models by using the bacteria that are most
commonly associated with the disease to better replicate the disease process.

1.1.f. Pathogenesis: Bone Loss
A critical hallmark of periodontal damage is alveolar bone loss. Bone resorption is
mediated by osteoclasts (OCs), while bone formation is mediated by osteoblasts (OBs).
Under normal homeostatic balance, OBs and OCs constantly signal to each other to
maintain a constant level of bone turnover. More specifically, osteoblasts produce
receptor activator of nuclear factor kappa b ligand (RANK-L), which is a critical activator
of osteoclasts. On the other hand, osteoblasts also secrete osteoprotegerin (OPG), which
can inhibit the RANK-L signal by irreversibly binding to its receptor.68 In periodontal
disease, there is imbalance in this process, and a net catabolic effect occurs by an
increased osteoclast to osteoblast activity ratio.69 In fact, osteoclast formation can be
induced by pro-inflammatory cytokines secreted by both innate and adaptive immune
cells, such as TNF-α and IL-1.70 These same cytokines have been shown to deactivate
osteoblasts, directly linking inflammation to the osteoblast-osteoclast activity ratio.69
Additionally, macrophage colony stimulating factor (M-CSF) is a pro-inflammatory
cytokine critical for the activation of both macrophages and osteoclasts,71-72 that is
secreted primarily by osteoblasts in response to pro-inflammatory signals.73 This results
in an iterative cascade of macrophage and osteoclast activation which eventually results
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in inflammatory-driven bone loss. Thus, in hyper-inflammatory conditions, osteoclast
actions are heightened more than osteoblast actions, resulting in a net loss of bone.
(Figure 2)
1.1.h. Treatment Modalities
Current and traditional therapy to treat periodontal disease includes scaling and
root planing (SRP).74 Scaling involves mechanical debridement of plaque biofilms and
calculus from clinical crowns using scalers, and root planing requires access to the root
surfaces using surgical and non-surgical measures for the same purpose.75 This
treatment has undergone continual refinement to involve an extensive array of
instruments including ultrasonic scalers, which use ultrasonic energy to assist in removal
of biofilms,76 although the foundational technique and principles have not changed since
its conception. The basic concept is that by disrupting plaque biofilms, the host immune
system will discontinue its attack on this altered environment and the tissue inflammation
and subsequent cellular damage will stop. Unfortunately, complete removal of the entirety
of the plaque by clinicians is highly unlikely,77 and nevertheless there are some patients
who recur after therapy76. In fact, in aggressive periodontitis (currently referred to as
stage III.C periodontitis), clinical attachment loss occurs in patients with a very limited
plaque load.78 Due to the limited ability of SRP to completely heal the entire periodontally
diseased population, several adjunctive therapeutics have been developed over the
years.
Initially, extensive research was conducted testing the use of systemic
antimicrobial therapy for treatment of periodontal disease. Over the years, several
antibiotics have been tested for treatment of PD, such as penicillin, augmentin,
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clindamycin,

amoxicillin,

metronidazole,

tetracycline,

doxycycline,

minocycline,

azithromycin and more.79-83 Considering that antibiotic overuse has led to a widespread
issue with antimicrobial resistance,84-85 the marginal benefits have limited the use of
systemic antibiotic use to severe cases of disease.86 Local antimicrobials have been
shown to be less effective than systemic antimicrobials but nevertheless are still used
clinically.87 For example, PerioChip® and Atridox® are both bioresorbable discs either
loaded with chlorhexidine gluconate or doxycycline hyclate, respectively. 88 Arestin® is
minocycline hydrochloride loaded in extended release nanoparticles.89, Periogard® is a
chlorhexidine mouth rinse formulation.90 Unfortunately, clinically relevant improvements
are not generally produced by using these drugs, and they still carry unwanted side
effects.91 Because of these factors, local antimicrobials are not currently considered
standard of care treatment, although they are commonly implemented as a last resort for
desperate and severe cases.92
Because the host immune response is the source of tissue destruction in
periodontal disease, extensive research has been conducted toward targeting the host
immune response. Several groups have demonstrated that non-steroidal antiinflammatory drugs (NSAIDs) are efficacious in reducing periodontal destruction. For
example, indomethacin and flurbiprofen have been shown effective in reducing
periodontal destruction when given systemically in animals.93 Interestingly, even topical
application of an NSAID can reduce the destructive effects of periodontal disease.94
Unfortunately, some of these effects were marginally significant, and when taken into
clinical trials, were unable to produce statistically significant increases in clinical
attachment or bone regeneration.95 While NSAIDS are an obvious choice considering
significantly more prostaglandins have been found in the gingival crevicular fluid of more
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aggressive and destructive periodontal diseases,96 many cell types are at play and play
a contributing role in the pathogenesis of the disease that are not directly involved in the
COX pathway. Additionally, NSAIDs have consistent side effects and chronic use is
generally contraindicated to prevent damage.97 Nevertheless, further exploration of
treating periodontal disease with NSAIDs is ongoing and could produce exciting data in
the future. Most recently, an innovative cyclic treatment schedule has been used,
reducing bone loss and inflammation in a randomized controlled clinical trial.98
In addition to NSAIDs as host modulation therapy, many studies have suggested
that inhibition of matrix metalloproteinases (MMPs) represent a promising therapeutic
strategy for treating periodontal disease. MMPs are enzymes mainly secreted by
fibroblasts that are responsible for maintenance of tissues through breakdown of
extracellular matrix components.99 There are 23 different MMPs, all of which are
endogenously inhibited by tissue inhibitors of MMPs (TIMPs).100 MMP-2, -8, -9 and -13
are commonly studied with respect to periodontal disease because they are increased in
either the gingival crevicular fluid or gingival tissues of periodontally diseased
individuals.99 In periodontal disease, the MMP/TIMP ratio is increased resulting in a net
breakdown of tissues.101 Although doxycycline was originally designed as a semisynthetic tetracycline, at sub-antimicrobial doses this compound has been shown to
inhibit matrix metalloproteinases -8 and -13, and therefore has been marketed for
treatment of periodontal disease as a host modulation therapy under the trade name
Periostat®.102 Minocycline is another tetracycline analogue103 that has been evaluated as
an MMP inhibitor in several diseases such as multiple sclerosis, vascular neurological
disorders as well as periodontal disease.104 Small molecule MMP inhibitors have also
been developed, such as batimastat, marimastat, prinomastat and rebimastat.105 Lastly,
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monoclonal antibodies to MMPs have been developed and are currently being evaluated
for treatment of tumor metastases.106-107 These antibodies will likely be evaluated for host
modulation therapy for periodontal disease in the near future.
Bisphosphonates (BPs) present an additional potential therapeutic class that could
help mediate periodontal health in the over-inflamed host. BPs are pyrophosphate
analogues that adsorb selectively to hydroxyapatite surfaces in bone and prevent
breakdown of bone tissue through multiple independent mechanisms.108 In short, BPs
inhibit osteoclast function and recruitment, leading to a reduction in alveolar bone loss.109
Thus, these compounds have been implicated in diseases where bone loss is a clinical
issue such as osteoporosis,110 osteogenesis imperfecta111 and periodontal disease.112
Bisphosphonates have even been shown to exhibit anti-tumor activity through decreasing
production of VEGF, inhibiting cellular proliferation and causing cell cycle arrest. 113
Unfortunately, osteonecrosis of the jaw (ONJ) is a common adverse outcome associated
with bisphosphonate use. First described in 2003,114 bisphosphonate related
osteonecrosis of the jaw (BRONJ) is an area of uncovered bone persisting for at least 8
weeks in the maxillary and mandibular bones. The pathophysiology of the disease is
poorly understood but several theories have been proposed115 including avascular
necrosis, drug toxicity, reduced bone turnover due to compromised osteoclast-osteoblast
interactions as well as inflammation such as is seen in periodontal disease.116 More
recently, ONJ has been linked to the usage of anti-resorptive medications other than just
bisphosphonates and thus has been renamed medication related osteonecrosis of the
jaw (MRONJ).117 Second to BPs, ONJ is commonly seen in patients taking denosumab,
a monoclonal antibody targeting RANK-L.118 While several additional medications have
also been shown to correlate with ONJ incidence,119 periodontal disease has been
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correlated with disease development.120-122 Considering these facts, the potential use of
an anti-resorptive medications to treat periodontal bone loss has been employed with
extreme caution.
Based on the data presented above, there is an urgent need for development of
novel treatment strategies for periodontal disease. The ideal agent would be a small
molecule that could be applied topically, would interrupt the pathways that activate the
inflammatory response, and prevent bone loss. This dissertation will describe our
attempts to develop such an agent through structure-based design and structural
optimization of potential lead compounds.
1.2. Epigenetics
1.2.a. Introduction
The term epigenetics refers to reversible and heritable changes in the expression
of DNA that do not involve changes in the primary DNA sequence. Over the last decade,
there has been a dramatic increase in the study of epigenetic control mechanisms that
play a role in the development of cancer and other diseases. The first epigenetic targeting
therapeutic was technically FDA approved in 1968, but the fact that this drug, 5azacytidine, acted through an epigenetic mechanism was only discovered in 2004.123 In
that same year, the first reversible histone demethylase enzyme, KDM1A, was
discovered.124 Since then, a plethora of additional epigenetic modifying enzymes have
been discovered, and various epigenetic mechanisms have been targeted for treatment
of various diseases.
Epigenetics contrasts with genetics, the study of inherited DNA alterations,
because epigenetic modification does not alter the DNA but rather alters the differential
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expression of specific genes. Epigenetic changes are generally initiated in response to
internal and external stimuli, and these processes are mediated through several different
mechanisms within a cell. There are two basic mechanisms for the epigenetic control of
gene expression: methylation of DNA at CpG islands in promoter regions of DNA and
post-translational modification of histone proteins. The focus of this dissertation is on
histone methylation/demethylation, specifically the demethylation activity of KDM4B and
to a lesser extent KDM1A. This section will explore the general concepts of epigenetics,
the mechanism of KDM4Bs enzymatic activity, some of the effects of that activity and
finally how and why KDM4B has been targeted for drug development.
1.2.b. Histone Modifications
DNA is organized into tightly wound chromatin so that it can fit into the nucleus of
a cell. Chromatin can either be relaxed euchromatin or condensed heterochromatin,
depending on how tightly DNA is bound around nucleosomes, and this alters the
accessibility of transcriptional machinery for purposes of replicating and expressing these
genes. Nucleosomes consist of histones H1, H2A, H2B, H3 and H4, each of which has
amino-terminal tails that are accessible for modification. (Figure 1.3) Histone methylation
and acetylation are widely studied, while phosphorylation, ubiquitination, sumoylation and
citrullination of histone tails have been less well characterized. These groups are generally
transferred to very specific histone tails by “writers” and to be removed require an entirely
separate set of very specific enzymes called “erasers”. For example, histone
methyltransferase G9a is a writer capable of specifically transferring methyl groups to
histone 3 lysine 9 (H3K9) and is only active in converting the mono-methylated form into
the di- or tri-methylated form.125 On the other hand, to remove these marks requires an
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eraser: histone demethylase KDM4B. To add to the complexity, the specificity of these
enzymes is not always overlapping, as KDM4B has additional activity on the trimethyl state
of histone 3 lysine 36 (H3K36me3) non-concurrent with G9a’s additional activity on
H3K27. Once specific tails are modified, the modifications are read by yet another set of
enzymes called readers, which are most commonly bromodomains. (Figure 1.4) In cancer
and other diseases, DNA promoter hypermethylation in combination with abnormal
histone modifications have been associated with the aberrant silencing of genes.126-128
Epigenetic gene silencing, in combination with gene mutations, are critical mechanisms
involved in the etiology and progression of virtually all cancers.126 Aberrant regulation of
these processes can lead to silencing of tumor suppressor genes important in the
development of cancer, and thus multiple chromatin remodeling enzymes have been
targeted for the discovery of novel antitumor agents. 129-131 More recently, dysregulated
epigenetic modulation has been shown to be a factor in diseases other than cancer. The
focus of this dissertation is the histone demethylase enzyme class and its relation to the
immune response in periodontal disease. The histone demethylases can be further broken
down into FAD dependent (KDM1) and independent enzymes (KDM2-6). The FADindependent histone demethylases have a jumonji C domain responsible for their catalytic
activity whereas the FAD-dependent use FAD as a cofactor and commonly form
complexes to enhance their catalytic activity.132
1.2.c. KDM1A
The first discovered and most extensively studied FAD-dependent histone
demethylase enzyme is KDM1A, also known as lysine-specific demethylase 1 (LSD1) The
primary function of KDM1A is to remove methyl groups from the activating chromatin mark
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histone 3 lysine 4 (H3K4). KDM1A is specific for the substrates monomethyl histone 3
lysine 4 (H3K4me) and dimethyl histone 3 lysine 4 (H3K4me2). H3K4 methylation states
are generally correlated with active transcription, where higher methylation (trimethylation)
is found on highly active genes.133 KDM1A is also known to demethylate histone 3 lysine
9 (H3K9) when co-localized with the androgen receptor in prostate tumors,134 and also
has
non-histone protein substrates such as p53 and deoxynucleic acid methyltransferase 1
(Dnmt1).135 A number of effective KDM1A inhibitors have been identified, and include
tranylcypromine-based irreversible inhibitors such as GSK2879552136 and ORY-1001,137139

oligoamines such as verlindamycin140 and related isosteric ureas and thioureas,141-142

reversible benzohydrazide inhibitors such as SP-2509,139 reversible 1,2,4-triazoles,143 and
dithiocarbamate-urea hybrid KDM1A inactivators.144 KDM1A is now regarded as an
emerging drug target for diseases other than cancer, such as neurological disease, 145-146
blood disorders,147-148 viral infection,149 diabetes150-151 and fibrosis.152. The primary process
KDM1A controls is cell proliferation and cell cycle regulation, and thus it has primarily been
studied as a regulator in cancer cell progression and growth. It is clear that while KDM1A
has several important regulatory functions, the potential of targeting this enzyme for
treating human disease is in its infancy, and as time progresses it is certain that there will
be development of further uses of inhibiting KDM1A as well as more and more potent
KDM1A inhibitors.
Relevant to the current discussion, KDM1A has more recently been linked to the
host immune response. For example, KDM1A expression is reduced upon TLR activation
and subsequent inflammation, leading to endotoxin shock.153 In the absence of KDM1A,
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Figure 1.3. Modifiable sites on histones.

Figure 1.4. Writers, readers and erasers: some common examples and their main function.

hyperinflammation ensues causing host damage.153 Also, KDM1A is critical for activation
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of B cells, and when KDM1A is ablated in these cells, immune response genes are
overactivated.154 Agonizing histone demethylases is very difficult, and since the activity of
KDM1A is correlated with immune suppression, we sought to determine a druggable target
that would keep KDM1A active. More recently, Boulding et. Al showed that introduction of
a KDM1A inhibitor promotes expression of M1 markers and decreases M2 markers.46

1.2.d. KDM4B: Introduction
The KDM4 family of epigenetic modifiers target the demethylation of histone 3
lysine 9 and 36, as well as histone1.4 lysine 26. Each member contains a jumonji C (jmjC)
domain responsible for the demethylation activity, and uses Fe2+, 2-oxoglutarate and O2
for this activity.155 (Figure 1.5) Only family members KDM4A-C contain double PHD and
Tudor domains, and these differences are thought to attribute to the variable specificity
between A-C compared to isozymes D-F. KDM4A-C have a 5-fold specificity for H3K9
over that of H3K36 and H1.4K26. KDM4B exhibits the lowest rate of demethylation within
the family, for reasons that are not clear. KDM4D-F are half the size of other family
members and are unable to demethylate H3K36.156 As shown above, demethylation of
histone lysines occurs through a well-defined mechanism that is conserved among
enzyme superfamily. First, ferrous iron binds to the active site by coordinating with one
aspartic/glutamic acid and two histidines as well as water. 2-oxoglutarate (2-OG) then
binds displacing some water, followed by binding of the histone lysine which displaces the
remaining water that is bound to iron. This activates iron to undergo an oxidative
decarboxylation reaction, generating Fe(IV) and CO2. Fe(IV) is then able to demethylate
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Figure 1.5. Mechanism of KDM4B-mediated demethylation.

the histone lysine, producing formaldehyde through a hemiaminal intermediate. The 2-OG

26

is converted to succinate through this process and once it is released, ferrous iron is
regenerated, allowing for further demethylation.132
Trimethylation of H3K9 and H1.4K26 are classically thought to be repressive
heterochromatin marks. This contrasts with H3K36 methylation which generally correlates
with active expression.156 The mechanisms underlying various histone methylation
patterns and the enzymes involved in repressing or activating genes are yet to be
understood, but there is substantial evidence supporting the idea that histone modifying
enzymes exhibit crosstalk behavior, and also influence DNA methylation activity.
Additionally, the activity of an epigenetic enzyme can have an influence on more than just
histone lysines. These enzymes have been implicated in processes such as cytosolic and
nuclear protein modifications, alternative splicing, as well as recruitment of other proteins
for complex formation.
1.2.e. KDM4B: Immune Response
KDM4B and its primary substrate, histone 3 lysine 9 (H3K9), have been implicated
in numerous immunological processes. For example, trimethylation at H3K9 has been
shown to contribute to the repression of TLR4 expression.157 In addition, TNFα
transcription is repressed through H3K9 methylation during the process of endotoxin
tolerance.158 Also, H3K9me3 levels are decreased in macrophages through exposure to
high glucose, accompanied by a simultaneous increase in inflammatory cytokine
production.159 H3K9me3 levels are also found to be increased in response to hypoxia,
which downregulates mRNA expression of the chemokine Ccl2 and the chemokine
receptors Ccr1 and Ccr5.160 Additionally, decreased levels of H3K9me3 is associated with
increased TLR4-mediated expression of pro-inflammatory cytokines through recruitment
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of NF-κB p65 to their proximal promoters.161 Dulal Das et al reports that KDM4B
knockdown recruits repressive methylation marks to the promoters of IL-1β and IL-2 genes
among others in neural stem cells.162 IL-1β is an extremely important cytokine in the
regulation of periodontal disease pathogenesis, and its transcription is prolonged by the
bacterial challenge present in the plaque of diseased patients.163 KDM4B has also been
shown to promote osteogenic over adipogenic differentiation of mesenchymal stem
cells.164 Helicobacter pylori is the major etiological factor for development of gastric
cancer, and a recent study found that H. pylori induces KDM4B overexpression in gastric
tissues. The chronic inflammation seen in these tissues that leads from gastritis to gastric
cancer is through NF-κB and COX-2, and this action is directly dependent on KDM4B
demethylation activity.165 Although this data supports the idea that KDM4B activity is
correlated to hyper-inflammation, further studies are needed to fully define the
immunomodulatory mechanism of KDM4B in the context of periodontal disease.
The KDM4 family is said to be able to demethylate H3K23me3, an underexplored
chromatin mark. This allows for H3K36 demethylation activity to occur, which is an
important epigenetic control point for meiosis and spermatogenesis. In relation to
immunity, H3K36me2 expression results in expression of genes that promote plasma cell
transformation.166 H3K36 methylation has also been associated with macrophage
polarization, and increased methylation at this mark results in suppressed production of
IL-6 and TNF-α by macrophages.167
In addition to the traditional epigenetic mechanisms at play, KDM4B may
functionally be linked to the immune response through immunometabolism. KDM4B is a
target for hypoxia inducible factor 1 alpha (HIF-1α) in response to hypoxia.168 HIF-1α-
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dependent transcription is induced upon lipopolysaccharide pro-inflammatory stimulus
and results in an increased glycolytic metabolic program in macrophages.169 The M1
macrophage is a major immune cell responsible for inflammation. The expression of
isocitrate dehydrogenase is decreased 7-fold in M1 macrophages compared to M0
macrophages.170 This is the enzyme that converts citrate to alpha ketoglutarate (α-KG,
also known as 2-oxoglutarate, 2-OG), which is a cofactor for KDM4 family of enzymes. In
addition, α-KG is a source of glutamine and glutamate, and therefore plays a role in
immunity through increases in immune cells and their respective activity.171 If less α-KG is
available to contribute to these protective immune responses secondary to depletion by
KDM4, it can be said that KDM4 contributes to the loss of the protective immune response
provided by glutamine and glutamate through competition for α-KG.
1.2.f. KDM4B: Drug Discovery
The focus of epigenetic-based drug discovery research has been mainly directed
towards histone deacetylases (HDACs) in the treatment of various cancers. More recently,
the KDM4 family of epigenetic modifying enzymes have been found to be linked to positive
regulation of many immunological processes, and therefore serve as an interesting target
for development of hyperinflammatory or autoimmune disorders. Unfortunately, drug
development in the realm of immunity has not been initiated, though development of
KDM4 inhibitors for treatment of prostate and breast cancer continue to progress. The first
series of inhibitors of the KDM4 family were based on 2-oxoglutarate (2-OG) 1 because
of it’s critical role in the catalytic activity of the enzyme. N-oxalylglycine (NOG) 2 and 2-4pyridine dicarboxylic acid (2-4-PDCA) 3 have been shown to inhibit various KDM4 family
members by chelating iron, but are not selective and target many additionally related and
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unrelated enzymes.172 JIB-04 4 was the first KDM4 inhibitor that was not a 2-OG
competitive inhibitor, and although it is a pan JmjC KDM inhibitor, it has no activity toward
KDM1A or other epigenetic enzymes, proving useful for mechanistic studies. 173 More
recently, the 8-hydroxyquinoline (8-HQ) scaffold was identified as a hit through highthroughput screening.174 These studies identified IOX1 5 as a potent KDM4 inhibitor but
this drug has poor cell permeability and has to be used as a prodrug methyl ester.175 Based
on this scaffold, several groups developed successful drugs, including the NIH Molecular
Libraries program, which developed an extremely potent inhibitor, ML324 6.176 Selective
targeting of specific KDM4 family enzymes has yet to be successful, and the structure
activity relationships that govern selective binding are yet to be understood. Additional
analogues of ML324 were developed that have variable selectivity within the KDM4
family.177 Other groups have identified additional compounds able to inhibit the KDM4
family such as NSC636819 7, a dinitrobenzene,178 circuminoids,179 pyridinyl thiazoles180
and others, highlighting the diversity in available inhibitors and consequently the infancy
in which KDM4 drug discovery exists. Studies describing development of KDM4 inhibitors
rarely test the compounds for all of the KDM4 family members, and none have evaluated
their inhibitors in both male and female samples, despite the association of these enzymes
with sex-specific hormonal signaling pathways.181-182 (Figure 1.5)
1.2.g. Epigenetic Coordination Mechanisms
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As new epigenetic enzymes are discovered that possess different targets for
regulating cellular processes, finding a definition of the epigenetic landscape, which
encompasses

all

chromatin
remodeling
processes as well
as

crosstalk

between epigenetic
enzymes
marks,

and
will

be

attempted. It has

Figure 1.6. Compounds known to interact with KDM4B. Compounds 1-3 are
previously published KDM4B inhibitors. Compound 4 is a KDM1A inhibitor.

been known for some time that epigenetic enzymes themselves can be epigenetically
modified, which suggests a checks and balance system or a compensatory mechanism
by which our cells can maintain homeostasis. On the other hand, when epigeneticallycontrolled cellular processes are dysregulated to a degree that is beyond repair, small
molecule therapeutics may be indicated to revert cells into a homeostatic state.
Uncovering the entirety of this landscape will allow for understanding of how the histone
modification system within our cells is responsible for making the changes necessary to
drive an undifferentiated stem cell into a fully differentiated state.
Histone demethylase enzymes conserved among diverse species, but these
enzymes are commonly redundant, sharing substrate specificity among different classes
and families, as well as coordinated in their activity. For example, the demethylation
activity of KDM1A on H3K4 leads to repression of pro-inflammatory cytokine gene
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transcription.183 Interestingly, previous data has shown that cross talk between KDM4B
and KDM1A enzymes leads to a balanced system wherein lysine 9 methylation serves as

Figure 1.7. Proposed KDM4B-mediated immunomodulation mechanism. Coordination between KDM1A and
KDM4B results in compensation between the two to ensure either active or repressed transcription.

a prerequisite to lysine 4 demethylation by KDM1A.184 In other words, when KDM4B is
active at the H3K9me3 mark, KDM1A cannot be concurrently active at H3K4me2, and
vice versa.184 KDM4B is then a positive regulator of the pro- inflammatory cytokine
response through an indirect mechanism by inhibiting KDM1A. The link between these
two histone marks is coupled to H3K9Ac levels, as has been additionally demonstrated in
human CD4+ T cells. In this situation, T cell receptor stimulation induces pathologic FasL
production proportional to the amount of H3K9 demethylation, H3K9 acetylation and H3K4
methylation.185 Therefore, we are able to use coordination between mutually exclusive
histone demethylases to antagonize one and indirectly agonize another.
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1.3. Sex Differences
It is well known that sex plays a key role in the acquisition and progression of
immune diseases. More specifically for periodontal disease, 56% of men have the disease
compared to only 38% of females. Furthermore, 16.5% of male patients manifest with
severe disease compared to 7.6% of females.186 In general, females are thought to have
superior functioning immune systems with responses more appropriate to clear the
antigens and cause no further damage. For example, males are known to produce more
damaging TNF-α in response to LPS, while females are known to be more efficient at
antigen presentation. Additionally, circulating sex hormones may influence immune
signaling, as there are estrogen and androgen response elements on the promoters of
many acute inflammatory genes. Testosterone is generally immunosuppressive and is
found in higher amounts in post-pubertal males than females. On the other hand, estrogen
has an immune activating effect, increasing production of IL-1, IL-6 and TNF-α by
macrophages.187
KDM4B regulates sex hormone signaling events. Current literature suggests that
KDM4B can modulate cell signaling during androgen receptor (AR) mediated cancer
growth and suppression, suggesting that KDM4B inhibition affects androgen receptor
signaling leading to cancer cell death. More specifically, Coffey et al concluded that AR is
depleted in response to KDM4B knockdown, and in turn KDM4B is required for the
transcriptional activity of AR.188 Additionally, while KDM1A is overexpressed in breast
cancer and its activity upregulates ER transcription,189 KDM4B has been identified as an
estrogen receptor co-regulator and its inhibition limits breast cancer growth via GATA-3
co-activation.190 KDM4B is also required for mammary gland development as well as
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estrogen dependent cell proliferation and growth.191 Despite these facts, ongoing research
does not address the differential effects of sex on KDM4B signaling and immune
processing. Wang et al. recently reported that KDM4A is required for M1 macrophage
polarization in RAW264.7 macrophages, and that pharmacologic inhibition of the KDM4
family induces apoptosis in these cells.47 Unfortunately, RAW264.7 macrophages are a
male murine cancer cell line and therefore this data cannot be generalized to males and
females. Additionally, Choi et al. demonstrated that ML324 treatment blocks TNF-α
mediated neutrophil adhesion, a process critical for immune response propagation, but
only conducted the experiment in male mice.192 Thus, in addition to the importance of
studying sex differences in periodontal disease, KDM4B also likely has sexual dimorphic
characteristics; therefore, the work presented in this dissertation has been done in both
sexes wherever possible, to account for these potential factors.
1.4. Systemic disease
Periodontal disease has been linked to several systemic diseases, which may
have an underlying epigenetic component driving their correlation. One systemic disease
which has been extensively linked to periodontal disease is diabetes mellitus (DM), a
disease where the body’s insulin is improperly managed, resulting in excessive blood
glucose levels. This link has been attributed to several factors, but the most prominent is
that both PD and DM patients exhibit a hyper-inflammatory state. For example, diabetic
and obese patients exhibit higher serum levels of IL-6 and TNFa.193 Additionally, diabetic
patients have higher IL-1b and PGE2 in their gingival crevicular fluid.194 Interestingly,
monocytes from diabetic patients exhibit a hyper-inflammatory state, secreting higher
concentrations of pro-inflammatory cytokines that drive PD in response to LPS than
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monocytes from non-diabetic individuals.195 KDM4B inhibition results in methylation of
H3K9 and is required for deacetylation at H3 and H4.196 This switch from methylation to
acetylation at H3K9 is activated by p38 MAPK, by phosphorylating lysine
methyltransferase 1A (KMT1A) and disabling its interaction with target genes. 197 P38
MAPK has long been known to positively regulate the immune response, but only more
recently has the role of H3K9ac been characterized as a contributor to this activity.
H3K9ac is increased in macrophages from diabetic mice, and this mark drives
STAT1/MyD88 expression and subsequent sterile inflammation found in diabetes. 198
following hyperglycemic treatment, expression of SUV39H1, one of the histone
methyltransferases that acts on H3K9, is decreased. Alternatively, glucose treatment
recruits KDM1A to the NF-κB p65 promoter, an observation that has previously been
shown to induce inflammatory cytokine expression. Interestingly, hyperglycemia increases
H3K4 methylation and decreases H3K9 methylation, a pattern consistent with what we
believe initiates immune dysfunction seen in periodontal disease.199 These data suggest
that the underlying link observed between diabetes and periodontal disease may be due
to a dysregulated histone code, specifically involving KDM4B and KDM1A.
In addition to diabetes, obesity has also been extensively linked to both periodontal
disease as well as epigenetic modifications. Obesity increases a patients risk of both
acquiring periodontal disease as well as more severe forms of the disease.200

For

example, systemic inflammation and periodontal disease parameters such as probing
depth induced by obesity can be decreased with dietary management.201 Additionally, oral
administration of the periopathogen P. gingivalis has effects on the gut microbiota, which
alters metabolism.202 In fact, obese patients have a completely different salivary
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microbiome than that of their healthy counterparts, including significantly increased levels
of the keystone pathogen genus prevotella.203 Simply feeding mice a high-fat diet results
in alveolar bone loss and increased pro-inflammatory cytokine production as compared to
feeding mice a normal diet.204 With regards to epigenetics, KDM4C is able to control
adipogenesis via repression of PPAR-gamma, and has consequently been identified as a
potential therapeutic for obesity or type 2 diabetes mellitus 205. KDM4B has also shown to
promote osteogenic over adipogenic differentiation of mesenchymal stem cells. This
potentially links the KDM4 family with both bone diseases as well as obesity
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. Not

surprisingly, two back-to-back 2009 studies demonstrated that KDM4B knockout mice
spontaneously develop obesity.206-207 When KDM4B is specifically knocked out in
adipocytes, these cells exhibit decreased energy expenditure as well as decreased
glucose and lipid metabolism.208-209 These data suggest that KDM4B may be dysregulated
in both periodontal disease and obesity, but cell-type specific activity of this enzyme may
be an important consideration for treatment of either disease.
1.5. Rationale for dissertation
Goals of the Proposed Research: Periodontal diseases (PD) affect 42% of the adult
American population and are characterized by bacterial-driven inflammatory bone loss.
Present adjunctive therapies to manage PD have limited clinical value, and in some cases
carry potential side effects that may outweigh their benefit. It is well known that histone
demethylases can modulate the immune response, but their correlation with periodontal
status is largely unknown

155, 183-184, 210

. The primary objective of this research is to define

the epigenetic profile of periodontal disease, specifically in the context of histone
demethylase 4B (KDM4B). Additionally, this proposal aims to develop KDM4B inhibitors
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with a greater ability to modulate PD pathogenesis through targeting inflammation and
bone loss.
1.5.a. Hypothesis. The demethylation activity of KDM1A on histone 3 lysine 4 results in
a reduction of pro-inflammatory cytokine transcription 183. The histone lysine demethylase
KDM4B

is

a

histone demethylase that

3 trimethyllysine 9 (H3K9me3)

to

reduce

demethylates histone

155

, but this demethylation activity is mutually exclusive of

demethylation of H3K4me2 by KDM1A
coordination

specifically

184

. This proposal will take advantage of this

pro-inflammatory

cytokine

transcription

by

promoting

KDM1A activity through KDM4B inhibition. The central hypothesis of this proposal is that
promotion of KDM1A activity by introduction of a specific KDM4B inhibitor will alleviate PD
inflammation and bone loss and that by controlling the overactive immune system in
diseased areas, it will enable the host to better manage the disease and prevent its
recurrence. We will test this hypothesis through completion of the following Specific Aims:
1.5.b. Specific Aims
1.5.b.1. Specific Aim 1: We will define the role of KDM4B in periodontal inflammation
and explore the mechanism by which these changes are mediated. KDM4B abundance
will be assessed in perio-pathogen activated inflammatory bone loss tissue sections. In
vitro, TNF-α and IL-6 response to A. actinomycetemcomitans LPS (Aa-LPS), a major
immunodominate surface antigen of a common perio-pathogen will be measured following
KDM4B inhibition with commercially available inhibitors. To further define the
immunomodulatory role of KDM4B, osteoclastogenesis will be measured in the presence
and absence of KDM4B inhibitors.

37

1.5.b.2. Specific Aim 2: We will use structure-based design techniques to discover novel
inhibitors of KDM4B for adjunctive treatment of PD inflammation. We will dock compounds
from large commercially available libraries to the crystal structure of KDM4B using a
modification of previously described techniques.211-212 As hits are identified, 2D orthogonal
mathematical models will be used to correlate immunomodulatory activity to structural
characteristics of compounds. Immune modulation will be phenotypically screened using
a primary macrophage model of PD. Top candidates will be synthesized and analyzed for
cytotoxicity and immunomodulatory potential in vitro. For effective compounds, IC50 values
will be determined.
1.5.b.3. Specific Aim 3: We will evaluate novel and known KDM4B inhibitors for
immunomodulatory activity in vivo. Promising KDM4B inhibitors, as well as the previously
defined KDM4B inhibitor (ML324), will be evaluated in a murine calvarial inflammatory
bone loss model of periodontal disease. Wild type C57BL/6 mice 12-14 weeks old will be
injected subcutaneously with fixed A. actinomycetemcomitans following pre-treatment
with drug or vehicle control in the mid-sagittal region of the calvarium every day for 5 days
to induce inflammatory bone loss. Compounds will be evaluated over a 100-fold
concentration range as defined by maximum tolerated dose, and bone loss will be
evaluated by micro-computed tomography. Tissues overlying the calvarial bones will be
analyzed for changes in histone methylation marks.
1.5.c. Impact on the Field. The proposed research will elucidate an underlying epigenetic
mechanism of PD pathogenesis and validate KDM4B as a drug target, thereby opening
new doors for drug development and allowing for an enhanced understanding of the interrelated functions of histone methylation and PD progression. This proposal may result in
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the development of a novel immunomodulatory compounds, which could be used in future
periodontal disease studies.

Chapter 2: Materials/Methods
2.1. Animal Care and Use
C57BL/6 mice were purchased from Jackson Laboratories and maintained in accordance
with NIH guidelines. Animals subject to food and tap water ad libitum and maintained
under normal 12-hour light cycles. Animals were euthanized via CO2 asphyxiation and
death verified by cervical dislocation. Experimental protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at the Medical University of South
Carolina under protocol number #2718.
2.2 Bacterial culture
Aggregatibacter actinomycetemcomitans strain Y4 was purchased from American Type
Culture Collection (ATCC) and grown following manufacturer’s protocols. A single colony
was selected by plating the bacterial suspension onto brain heart infusion (BHI) agar and
incubating for 3 days in a 5% CO2 incubator at 34 °C. A single colony was picked and
expanded in 10mL BHI broth overnight on a shaker. A growth curve was generated by
inoculating 10uL of this expanded solution into 20mL broth and monitoring the optical
density at a wavelength of 450nm every hour. At the mid-logarithmic growth phase,
bacteria were quantified using serial dilutions. Bacteria were expanded into 500mL and
diluted to OD450 = 0.3. Bacteria were centrifuged at 1500 x g for 10 minutes, washed with
PBS and fixed with 10% formalin for 30 minutes at room temperature. Formalin was
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removed by pelleting the fixed bacteria at 1500 x g and rinsing twice with PBS. Bacteria
were resuspended in PBS for in vitro experimentation and calvarial injections.
2.3 Murine Calvarial Model
Mice were anesthetized using isoflurane inhalation where fifteen uL of 12.5 or 20 μM of
ML324, 20 μM 36 or DMSO vehicle control in a 15 μL volume. One hour later, mice were

Figure 2.1. Murine calvarial model description.

anesthetized

using

isoflurane

and

2x109

CFU

fixed

Aggregatibacter

actinomycetemcoitans strain Y4, serotype b or phosphate buffered saline (PBS) vehicle
control was injected subcutaneously supraosteal to the mid-sagittal suture between the
eyes and ears to approximate the bregma point into 12-week C57BL/6 male mice.
Injections were repeated every 24 hours for 5 days. On day 6, 18 hours following the final
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injection, mice were euthanized and connective tissue and skin overlying the calvarial
bone was flash frozen, ground using a mortar and pestle and resuspended in M-PER
protein isolation buffer. Calvarial bones were fixed in 10% formalin for 24h and then stored
in ethanol for micro-computed tomographic analysis.
2.4 Protein Isolation and Immunoblotting
Protein was isolated from skin and connective tissue overlying the calvarial bone by flash
freezing tissues upon collection and immediately resuspending the ground tissues in 500
μL of mammalian protein extraction reagent (M-PER, Thermo fisher). Solutions were
sonicated at 4 ○C for 60 seconds and centrifuged at 1500 x g. Pellets were discarded and
supernatant solution containing protein was analyzed using a BCA assay. 25ug protein
was run on a SDS-PAGE gel along with Precision Plus Protein Dual Color standards (BioRad). Gels were transferred to a PVDF membrane using the trans-blot turbo transfer
system (Bio-Rad) and blocked in 5% fat-free milk in TBS-T overnight at 4 ○C. Blots were
incubated with primary antibodies in TBS-T overnight at 4 ○C. Blots were washed three
times in TBS-T and were incubated for 1 hour at room temperature with secondary
antibody in TBS-T. Blots were washed three times in TBS-T and developed using Azure
Biosciences ECL reagent. Blots were imaged using the Azure c600 imaging system and
densitometric analysis of protein was done using ImageJ software. Proteins of interest
were normalized to GAPDH as a standard.
2.5 mRNA isolation and qRT-PCR
Media was rinsed with PBS and cells were lysed using TriZol Reagent (Invitrogen,
Cat# 15596026). mRNA was isolated according to manufacturer’s protocols and purity
confirmed using a Nanodrop-1000 spectrophotometer (Thermo Fisher). Quantitative
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reverse-transcription real time polymerase chain (qRT-PCR) reaction was run using a
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat# 4368814)
followed by TaqMan® Fast Advanced Master Mix (Applied Biosystems, Cat# 4444557)
with TaqMan® Gene Expression Assay Primers (Applied biosystems, listed below) using
a StepOne Plus instrument (Thermo Fisher). TNF-α, IL-6 and the internal control GAPDH
were then quantitated for each sample in triplicate. Results are reported as fold change
(2-^^CT).
2.6 Cell Culture
All Cells were cultured at 37 ○C in 5% CO2.
2.6.a. RAW264.7. Cells were cultured in dulbecco’s modified essential medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. (P/S)
2.6.b. Primary Bone Marrow Macrophage Cell culture. Primary bone marrow was
cultured into macrophages as described previously 213. Briefly, bone marrow from left and
right femurs and tibiae of 12-14-week old wild type C57BL/6 mice was flushed into α-MEM
(Corning, Cat# 10-022-CV) supplemented with 10% fetal bovine serum (Hyclone, Cat#
SH30071.03HI) and 1% penicillin streptomycin (Sigma, Cat# P4333) and plated overnight
at 37 °C in 5% CO2. Cells remaining in suspension were differentiated into experimental
wells at a concentration of 2E6 cells/mL for 7 days or until 80% confluency and
homogeneity was achieved using macrophage colony stimulating factor (R&D Systems,
Cat# 416-ML-500), reconstituted in PBS + 1% BSA (Sigma, Cat# A8806) supplementation
(10ng/mL/48h). Cells at this point are referred to as bone marrow derived macrophages
(BMDMs).
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BMDMs were pre-treated with experimental KDM4B inhibitors for 1 hour at various
concentrations followed by incubation with Aggregatibacter actinomycetemcomitans
lipopolysaccharide (A.a LPS) for various time points (generally 8, 16 or 24h).
2.6.c. Primary Bone Marrow Osteoclast Cell culture.
Bone marrow stem cells were isolated from C57BL/6 mice, and differentiated into
osteoclasts as previously described 214-215. In brief, bone marrow isolated from femurs and
tibiae of 12 week-old wild-type C57BL/6 mice was plated overnight into phenol red free αMEM (Gibco, Cat# 41061-029). Adherent cells were discarded and cells that remained in
suspension were plated into the wells of a 96-well culture plate (Corning, Cat#3598) at a
density of 15,000 cells/well. Cells were supplemented with macrophage colony stimulating
factor (M-CSF, R&D Systems, Cat# 416-ML-500) (15ng/mL/48h) for 3 days followed by
supplementing with M-CSF (15ng/mL/48h) and receptor activator of nuclear factor kappa
b ligand (RANK-L) (R&D Systems, Cat# 462-TEC-010) (50ng/mL/48h) for 2 days. On day
5, wells were rinsed to remove RANK-L and replacement media was supplemented with
M-CSF (15ng/mL) with or without Aa-LPS (100ng/mL) or RANK-L (R&D Systems, Cat#
462-TEC-010) (50ng/mL) and ML324 (SelleckChem, Cat# S7296, 10μM) or DMSO
vehicle control for 72 hours.
2.7. TRAP staining and enumeration
Following osteoclast formation experiments, cells were rinsed twice, fixed with 10%
glutaraldehyde (Fisher, Cat# O2957-1) and stained for tartrate resistant acid phosphatase
(TRAP) as described in BD Bioscience Technical Bulletin No. 445 using a 10-minute
incubation with TRAP buffer. Subsequently, 3 representative images per well were
captured using an Eclipse TS100 microscope (Nikon) equipped with an Evolution MP
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camera (Media Cybernetics). Osteoclasts were quantified as multinucleated, TRAP+ cells
and statistically significant differences were computed using a paired one-way ANOVA
with multiple comparisons with an alpha of 0.05.
2.8. Cycloheximide Treatment
RAW264.7 macrophages were grown to 80% confluence in α-MEM supplemented with
10% FBS (Hyclone, Cat# SH30071.03HI) and 1% penicillin/streptomycin (Sigma, Cat#
P4333). Cells were then pre-treated with ML324 (SelleckChem, Cat# S7296, 50μM) or
DMSO vehicle control with or without cycloheximide (Sigma, Cat# C7698, 10μg/mL) for
4h. DMSO remained constant in each group at a level of 0.1% to eliminate interference
with the assay. Cells were challenged with A.a LPS (100 ng/mL) or PBS vehicle control
for 24 hours and collected for qRT-PCR analysis.
2.9. Immunofluorescence
RAW264.7 macrophages were grown to 80% confluence in phenol red free α-MEM
(Gibco, Cat# 41061-029) supplemented with 10% FBS (Hyclone, Cat# SH30071.03HI)
and 1% penicillin/streptomycin (Sigma, Cat# P4333) on Sensoplate Plus glass bottom
plates (Grenier Bio-One, Cat# 655892). Cells were pre-treated for 1 hour with test
inhibitors (SelleckChem, Cat# S7296, 50 μM) or DMSO vehicle control followed by A.a
LPS (100 ng/mL) for 24 hours. Cells were then rinsed with PBS and fixed using 4%
paraformaldehyde (Sigma) at 37 °C for 10 minutes. Cells were permeablized using 0.1%
Triton X-100 (Amresco, Cat# 0694) for 10 minutes and blocked using 3% Bovine Serum
Albumin (Sigma, Cat# A8806) in PBS for 30 minutes. Cells were then incubated for 1 hour
with rabbit anti-H3K4me (Active Motif, Cat# 39297, 1:750) in 3% BSA. Cells were rinsed
and incubated with fluorescent goat anti-rabbit antibody (AbCam, Cat# ab150078, 1:500)
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in 3% serum for 1 hour. Cells were counterstained with DAPI (VWR, Cat# 95059-474,
30μM) and AlexaFluor Phalloidin 488 (Invitrogen, A12379). Images were captured using
a Wiscan imaging system (Hermes). 32-36 Images per well were used for analysis (n = 3
wells/group).
2.10. Human Periodontal Tissue Procurement
This study was approved by the Institutional Review Board for the Health Sciences at the
Medical University of South Carolina, USA. Samples used for the present study represent
a subset of samples used for a larger study. Informed consent was obtained with all
patients prior to initiating study. Prior to surgery, clinical parameters were measured at the
same sites where tissues were harvested including: plaque Index (PI) on a scale of 0-3
(0-no plaque, 1-w/probe, 2-visible, 3-abundant)
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, gingival Index (GI) on a scale of 0-3

(0-no inflammation, 1-mild, 2-moderate w/BOP, 3-severe, spontaneous bleeding on
probing (BOP), pocket depth (PD), BOP, gingival recession (REC) and clinical attachment
level (CAL). Based on these parameters the inclusion criteria for the diseased group
consisted of at least 1 site with PD>4mm, GI 1-3 and PI 1-3. For the healthy controls
acceptable parameters were: PD≤4mm, GI≤1, and PI≤2. The exclusion criteria for both
groups included: smokers, unstable systemic diseases or chronic disorders (diabetes,
rheumatoid arthritis), patients using steroids, antibiotics, NSAIDS and/or other host
modulators. The procured samples were from tissues that would have been otherwise
discarded after periodontal surgery and or extraction sites. When clinically indicated,
procured tissues included connective tissue near the sulcular epithelium.
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2.11. Immunohistochemistry
Calvariae from mice with periodontal disease, collected as previously described
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were

formalin fixed, decalcified using 0.5 M EDTA, pH 8.0 for 2 weeks, paraffin embedded and
cut into 7 μm sections following standard protocols. Human periodontal tissues were
formalin fixed, paraffin embedded and cut into 7 μm sections following standard protocols.
Sections were permeablized using 0.2 M boric acid (Sigma, Cat# B6768). Tartrate
resistant acid phosphatase (TRAP) was measured as described in BD Bioscience
Technical Bulletin No. 445 following a 30-minute incubation with TRAP buffer. KDM4B
was visualized following blocking with 3% normal goat serum (SeraCare, Cat# 5560-0007)
using rabbit anti-KDM4B (AbCam, Cat# ab191434, 1:125) or rabbit anti-KDM4E (Novus,
Cat# NBP2-49124) overnight at 4°C. The sample was then incubated for 1 hour with
biotinylated goat anti-rabbit (Vectorlabs, Cat# BA-1000, 1:500). VECTASTAIN Elite ABC
HRP Kit (Vectorlabs, 1:500, Cat# PK-6100), and a DAB Peroxidase (HRP) Substrate Kit
(Vectorlabs, Cat# SK-4100) was then used for development. 15% Hematoxylin (Sigma,
Cat# H3136) was employed as a counterstain. Images were captured using a Nikon 80i
Eclipse microscope equipped with a DS-Fi1 camera. Region of interest selection and
subsequent quantification was performed using visiopharm software (n = 3) for calvarial
tissues. Human periodontal tissues were analyzed using imagej (n = 5-9).
2.12. JMJD2B Enzyme Assay
Inhibition of JMJD2B was assayed by BPS Biosciences using an 11-point IC50
determination using the histone demethylase AlphaScreen (PerkinElmer) assay (BPS
Bioscience, Cat# 50414). Briefly, enzymatic reactions were conducted in triplicate at room
temperature for 60 minutes in a 10 µl mixture containing assay buffer (BPS Bioscience,
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Cat# 52407), histone H3 peptide substrate, demethylase enzyme (BPS Bioscience, Cat#
50111), and ML324 or 2,4-pyridine dicarboxylic acid as a reference inhibitor. All wells had
a final DMSO concentration of 1%. After the enzymatic reactions were complete, antiMouse Acceptor beads (PerkinElmer, Cat# AL105C, 1:500) and Primary H3K9me3
antibody (BPS Biosciences, Cat# 52140E, 1:200) were added and samples were mixed.
The reactions were incubated for an additional 30 minutes followed by addition of
AlphaScreen Streptavidin-conjugated donor beads (PerkinElmer,Cat# 6760002S, 1:125).
30 minutes later the samples were measured using an AlphaScreen microplate reader
(EnSpire Alpha 2390 Multilabel Reader, PerkinElmer). In the absence of the compound,
the intensity (Ce) in each data set was defined as 100% activity. In the absence of enzyme,
the intensity (C0) in each data set was defined as 0% activity. The percent activity in the
presence of each compound was calculated according to the following equation: %activity
= (C-C0)/(Ce-C0), where C is the A-screen intensity in the presence of the compound. A
plot of % activity versus concentration was then constructed using non-linear regression
analysis of the sigmoidal dose-response curve generated with the equation Y=B+(TB)/1+10((LogIC50-X)×Hill Slope), where Y is percent activity, B is the minimum percent activity, T
is the maximum percent activity, X is the logarithm of compound concentration and Hill
Slope is the slope factor/Hill coefficient. The IC50 value was determined as the
concentration causing half-maximal percent activity.
2.13. Enzyme-Linked Immunosorbent Assay (ELISA)
Following cell culture experiments, supernatant proteins were collected for analysis by
ELISA. Standardization of samples was based on cell count at the initiation of
experimentation, and samples were kept at -80 ○C until use if not used immediately.
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Samples were centrifuged at 1500 x g to remove insoluble contaminants. 96 well plates
were coated with capture antibody overnight, washed three times and blocked with 1%
BSA for 2 hours. After washing, samples were added to plates in a 100uL sample volume.
Dilutions of samples were only done when necessary, in a subsequent assay if
concentrations were not within the linear range of the standard curve. After a 2 hour
incubation, plates were washed and a detection antibody was added and plates were
incubated for 1 hour. Plates were washed and incubated with streptavidin:HRP for 20
minutes. Plates were washed and developed using proprietary color reagents from R&D
Biosystems. Development was stopped by the addition of 2N H2SO4 and plates were read
using a Spectramax plate reader at 560nm. Plates were normalized to a blank well when
possible. A standard curve was fit using a log-log algorithm within the spectramax software
and concentrations were determined for each sample. Significance was determined using
either One-way or Two-way ANOVA with multiple comparisons, when applicable.
2.14. Micro-Computed Tomography
Calvariae were dissected from surrounding tissues upon sacrifice and immediately
submerged in 10% formalin for fixation. Bones were incubated overnight at room
temperature on a shaker to ensure complete fixation. Solutions were replaced with 70%
ethanol to rinse and then stored for long-term analysis in a fresh solution of 70% ethanol.
Samples were sent to Maria Johnson at University of Alabama Birmingham for scanning.
Scans were run on a Scanco 40 instrument at a 15 μm resolution. A cylindrical region of
interest was selected centered around the bregma point and samples were thresholded
at a minimum intensity value of 3148HU based on control samples. Bone density was
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determined using Analyze Pro software and statistical significance was determined using
a Student’s t-test.

2.15. Computational Chemistry
2.15.a. Docking Experiments
DOCK6.5: The KDM4B crystal structure (PDB: 4LXL) was prepared using UCSF Chimera
following DOCK6.5 protocols.218 Ligands and water molecules were removed from the
crystal structure. The ZINC15 compound database was filtered using pre-defined subsets
of compounds: those with predicted in vitro activity in combination with compounds that
were purchasable.219 This library was further refined by generating descriptors in
Molecular Operating Environment (CGS) software in a high-throughput manner and
eliminating large numbers of compounds based on these unfavorable descriptors:
violation of one or more of Lipinski’s rules, molecular weight less than 250 and greater
than 500 g/mol, greater than 12 rotatable bonds, compounds with a formal charge <-2 or
>2 and the library was charged and energy pre-minimized for each structure based on
standard protocols. The compound library was docked using DOCK6.5 in an unbiased
manner by using the entire enzyme as the active site for docking in flexible mode with
1000 maximum orientations per computation. The compound library was concurrently
docked using Molecular Operating Environment in a rigid receptor dock constrained to the
active site identified by the site finder tool in MOE. Hits from both programs were ranked
based on the percentage of the maximum binding energy of each hit. Compounds that
ranked independently within the top 70% of both docking experiments were selected for
physicochemical clustering. OpenBabel descriptors were generated for the top 70%
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consensus hits using Chemmine cheminformatics online tools.220 Compounds were
clustered by similarity and hits clustered in the smallest clade containing ML324, JIB-04
and NSC636819 were selected for in vitro evaluation. This consensus docking strategy
was performed on a combinatorial library of novel compounds as needed to prioritize
synthetic efforts.
2.15.b. Quantitative structure activity relationship (QSAR) development
The phenotypic immunosuppressive screen data was converted into binary data using
statistical significance (P<0.05) determined by One-Way ANOVA compared to DMSO
controls as a cutoff. A contingency analysis was run on the tested compounds to identify
the 2D descriptors defined by MOE that were most highly correlated with activity. The top
12 descriptors from this analysis were used to map a quantitative structure activity
relationship algorithm and cross-validation was conducted using a leave one out method
following standard protocols. The model was applied to our combinatorial library to predict
activity.221-222
2.16. Synthetic Chemistry
2.16.a. General Procedures: All solvents and chemicals were reagent grade. Anhydrous
dichloromethane (DCM) and dichloroethane (DCE) were purchased from VWR. All
solutions were dried over anhydrous magnesium sulfate or sodium sulfate, solvents were
removed by rotary evaporation under reduced pressure. Solids used in dry reactions were
additionally freeze dried before use. Microwave reactions were run in a Biotage Initiator.
Flash column chromatography was carried out using pre-packed silica columns from
RediSep or SiliCycle and mixtures adsorbed onto ISOLUTE for elution. Purity of
compounds was >95% as determined by ultra-pure liquid chromatography analysis. NMR
50

spectra were recorded on a Bruker 400 MHz instrument using CDCl3, MeOD or DMSOd6
as solvents. Chemical shifts are reported in ppm relative to TMS (0.00 ppm) or solvent
peaks as an internal reference. Splitting patterns are indicated as follows: s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet.
All data are represented as geometric mean ± standard error of the mean (SEM) and
statistical significance was determined using One-Way ANOVA with multiple comparisons
(p<0.05).
2.16.b. Compound 2: 5-Chloro-2-[(E)-2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1yl]pyridine (JIB-04). Hydrazine hydrate (5.48 g, 171 mmol, 5.34 mL) was added to a
solution of 2,5-dichloropyridine 1 (0.21 g, 1.42 mmol) in pyridine (10 mL) and the reaction
mixture was refluxed for 6 h. The resulting suspension was dried in vacuo (rotary
evaporator), dissolved in dichloromethane and washed with a 50 mL portion of 1.0 N
NaOH and three 50 mL portions of water. The organic layer was dried over anhydrous
magnesium sulfate, filtered, and the solvent was removed in vacuo to yield 5-chloro-2hydrazinylpyridine 2 as a white crystalline solid (0.097 g, 47%)
A 20 mg portion of 2 (20 mg, 1.4 mmol) and benzoyl pyridine 3 (25.5 mg, 1.4 mmol) were
refluxed overnight in methanol (10 mL) with a traces of acetic acid. The resulting solution
was dried via rotary evaporator and crystallized from ethyl acetate to yield 5-Chloro-2-[(E)2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl]pyridine (JIB-04) 4 as fine yellow needles
(0.099 g, 23%).
2.16.c. Compound 16, 23-28: Biphenyl benzoyl chloride (3.6 mmol) was added to
aminobenzoate derivatives 17 (3 mmol) under reflux in toluene (25 mL) as previously
described.223 Reaction was refluxed for 4h and product was evaporated under reduced
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pressure by adding water continually until all toluene was removed. Product was extracted
from ethyl acetate rinsing with brine. The remaining organic layer was loaded onto a 25g
silica column and purified using flash chromatography with a solvent gradient from 0-100%
ethyl acetate in hexanes over 25 minutes. Fractions containing product 18 were combined
and identity of products were confirmed using UPLC and NMR.
The resulting ester 18 (1 mmol) was added to a microwave vial with LiOH (.5 mmol) and
dissolved in methanol and water (3:1, 10mL). The reaction was microwave irradiated at
100 ○C for 1-2 hours until the ester starting material was consumed. The reaction was
acidified, evaporated under reduced pressure, and vacuum filtered rinsing with cold HCl
to yield product 16, 23-28 as a white to off-white solid.
Final products were lyophilized and analyzed using UPLC for >95% purity and 1H NMR
for identification.
2.16.d. Compound 29-46 were synthesized using a modification of a previously described
technique.224 Derivatized trifluoroborates (0.25 mmol), derivatized bromobenzenes (0.25
mmol), and cesium carbonate (0.756 mmol) was combined with catalytic [1,1′Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane
(0.023 mmol) and the mixture was suspended in a degassed solution of THF and water
(1:10, 5mL) in a 20mL microwave vial. The reaction was vortexed briefly and irradiated in
a biotage initiator at 100 ○C for 1-2 hours until the starting material was consumed as
determined by TLC as previously described. The reaction mixture was evaporated under
reduced pressure, acidified using HCl and extracted 3x from DCM. The organic was dried
over sodium sulfate and adsorbed onto isolute for separation using flash chromatography
to yield an off-white solid. The resulting ester (1 mmol) was added to a microwave vial with
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LiOH (0.5 mmol) and dissolved in methanol and water (3:1, 10mL). The reaction was
microwave irradiated at 100 ○C for 1-2 hours until the ester starting material was
consumed. The reaction was acidified, evaporated under reduced pressure, and vacuum
filtered rinsing with cold HCl to yield a white solid 15.
Carboxylic acid 15 (2 mmol) was lyophilized and resuspended in dry DCE (10 mL) under
nitrogen in a flame dried flask. Oxalyl chloride (3.6 mmol) and catalytic DMF (5 drops)
were added to the reaction on ice and the solution was allowed to stir at room temperature
for 1-24 h until gas was no longer produced. The reaction generally turned yellow upon
formation of the carbonyl chloride in solution. DCE was removed under reduced pressure
using rotary evaporation to yield a bright yellow residue. The residue was resuspended in
dry DCM (10mL) and in a separate flask, Aminobenzoate derivatives 17 were dissolved in
dry DCM (10 mL) with TEA (8.2 equiv.). The basic aminobenzoate solution was added to
the benzoyl chloride under nitrogen via cannula transfer and the reaction was stirred at
room temperature under nitrogen for 1-24h until the amine starting material was consumed
as confirmed by UPLC. The reaction mixture was filtered to remove the TEA salt, and the
remaining liquid was extracted from ethyl acetate, rinsing sequentially with citric acid,
NaOH and brine. The remaining organic layer was loaded onto a 25g silica column and
purified using flash chromatography with a solvent gradient from 0-100% ethyl acetate in
hexanes over 25 minutes. Fractions containing product 18 were combined and identity of
products were confirmed using UPLC and NMR.
The resulting ester 18 (1 mmol) was added to a microwave vial with LiOH (0.5 mmol) and
dissolved in methanol and water (3:1, 10mL). The reaction was microwave irradiated at
100 ○C for 1-2 hours until the ester starting material was consumed. The reaction was
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acidified, evaporated under reduced pressure, and vacuum filtered rinsing with cold HCl
to yield product 29-46 as a white to off-white solid.
Final products were lyophilized and analyzed using UPLC for >95% purity and 1H NMR
for identification.
2.16.d. Spectroscopy for Synthesized compounds:
2:
Intermediate: 1H NMR (CDCl3) δ: 3.795 (s, 2H), 5.797 (s, 1H), 6.697 (d, 1H, J = 8.8 Hz),
7.422 - 7.450 (dd, 1H, J = 2.5, 8.8 Hz), 8.058 (d, 1H, J = 2.3 Hz). MS calcd for C5H6ClN3
144.03 [M + H+], found 144.02 [M + H+].
Final product: 1H NMR (CDCl3) δ: 7.260-7.356 (m, 2H), 7.397-7.466 (m, 3H), 7.536-7.587
(m, 4H), 7.506 (td, 1H, J = 1.6, 7.8 Hz), 8.136 (d, 1H, J = 2.2 Hz), 8.823 (dd, 1H, J = 4.9,
0.7 Hz), 13.301 (s, 1H). MS calcd for C17H13ClN4 309.09 [M + H+], found 309.41 [M + H+]
16:
Intermediate: 1H NMR (400 MHz, CDCl3) δ3.90 (s, 3H), 7.25 (m, 1H), 7.42 (t, 1H), 7.51
(t, 2H), 7.69 (m, 1H), 7.77 (t, 2H), 8.04 (m, 3H), 8.59 (d, 1H), 11.68 (s, 1H)
Final Product: 1H NMR (400 MHz, CDCl3)δ7.19-7.23 (t, 3H), 7.59-7.64 (t, 3H), 8.098.13 (m, 3H), 8.74, 8.76 (d, 1H), 8.87, 8.89 (d, 2H), 12.61 (s, 1H), 12.91 (s, 2H)
23:
Intermediate 1: 1H NMR (400 MHz, (CD3)2SO)δ 2.11 (s, 3H), 2.34 (t, 3H), 3.53 (s, 3H),
7.16 (t, 1H), 7.26 (t, 1H), 7.35 (m, 3H), 7.50 (q, 1H), 7.59 (q, 2H), 7.68 (t, 2H), 7.91 (d,
2H), 9.87 (s, 1H)
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Final product: 1H NMR (400 MHz, (CD3)2SO)δ 2.07 (s, 3H), 7.12 (t, 1H), 7.26 (q, 1H),
7.35 (q, 3H), 7.52 (q, 1H), 7.60 (t, 2H), 7.68 (d, 2H), 9.95 (s, 1H), 12.62 (s, 1H)
24:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.92 (s, 3H), 7.44 (d, 1H), 7.53 (t, 2H), 7.62
(d, 1H), 7.78 (m, 3H), 7.92 (d, 2H), 8.06 (d, 2H), 8.50 (q, 1H), 11.41 (s, 1H)
UPLC Rt: 7.022 minutes
Final product: 1H NMR (400 MHz, (CD3)2SO)δ 7.26(t, 1H), 7.40 (m, 3H), 7.60 (m, 3H),
7.73 (d, 2H), 7.88 (d, 2H), 8.54 (q, 1H), 11.85 (s, 1H), 13.99 (s, 1H)
25:
Final product: 1H NMR (400 MHz, (CD3)2SO)δ 7.25 (m, 2H), 7.37 (m, 3H), 7.54 (d, 1H),
7.61 (t, 2H), 7.69 (d, 2H), 7.91 (d, 2H), 10.04 (s, 1H), 13.01 (s, 1H)
26:
Final product: 1H NMR (600 MHz, CDCl3)δ 3.98 (d, 4H), 6.87 (q, 1H), 7.42 (t, 1H), 7.52
(q, 3H), 7.66 (m, 4H), 7.78 (t, 2H), 8.14 (q, 4H), 8.82 (q, 1H)
27:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.74 (s, 3H), 7.25 (m, 1H), 7.37 (m, 3H),
7.52 (m, 1H), 7.61 (t, 2H), 7.70 (d, 2H), 7.95 (m, 2H), 8.34 (t, 1H), 10.37 (s, 1H)
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 7.39 (d, 1H), 7.53 (m, 3H), 7.69 (m, 1h),
7.79 (t, 2H), 7.87 (t, 2H), 8.10 (m, 3H), 8.47 (d, 1H), 10.48 (s, 1H), 12.94 (s, 1H)

55

28:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.67 (s, 3H), 7.24 (d, 1H), 7.34 (t, 2H), 7.59(d,
3H), 7.69 (d, 2H), 7.81 (s, 4H), 7.92 (d, 2H), 10.45 (s, 1H)
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 7.42 (m, 2H), 7.54 (q, 2H), 7.68 (q, 1H),
7.78 (d, 2H), 7.84 (d, 2H), 7.89 (d, 2H), 7.93 (d, 2H), 7.99 (d, 1H), 8.09 (d, 2H), 10.44 (s,
1H)
29:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.84 (s, 3H), 7.19 (m, 1H), 7.26 (d, 1H),
7.34 (q, 2H), 7.45 (t, 2H), 7.54 (t, 2H), 7.63 (m, 2H), 7.82 (d, 1H), 8.17 (t, 1H), 8.85 (q,
1H), 11.71 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 7.24 (q, 2H), 7.35 (q, 2H), 7.44 (t, 1H), 7.54
(d, 2H), 7.66 (m, 2H), 7.83 (d, 1H), 8.06 (s, 1H), 8.82 (q, 1H), 11.71 (s, 1H)
30:
Final product: 1H NMR (400 MHz, CDCl3)δ 6.88 (q, 1H), 7.41 (d, 1H), 7.51 (t, 2H), 7.61
(t, 1H), 7.71 (d, 2H), 7.84 (d, 1H), 8.01 (d, 1H), 8.20 (q, 1H), 8.31 (s, 1H), 8.80 (q, 1H),
12.13 (s, 1H)
31:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.62 (s, 3H), 6.89 (m, 1H), 7.10 (q, 2H),
7.31 (q, 4H), 7.38 (m, 2H), 7.59 (t, 1H), 7.77 (q, 1H), 8.53 (d, 1H), 10.85 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 6.93 (t, 1H), 7.14 (m, 3H), 7.30 (m, 4H),
7.46 (m, 2H), 7.62 (d, 1H), 7.88 (d, 1H), 8.60 (d, 1H), 10.47 (s, 1H)
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32:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.00 (s, 3H), 3.71 (s, 3H), 6.98 (t 1H), 7.21
(m, 3H), 7.29 (q, 1H), 7.35 (m ,4H), 7.57 (q, 1H), 7.66 (q, 1H), 8.93 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 2.03 (s, 3H), 7.01 (d, 1H), 7.15 (d, 1H), 7.20
(t, 2H), 7.27 (t, 2H), 7.32 (d, 2H), 7.38 (t, 1H), 7.67 (t, 2H), 8.70 (s, 1H)
33:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.65 (s, 3H), 7.08 (m, 2H), 7.18 (t, 2H), 7.30
(m, 4H), 7.37 (t, 1H), 7.44 (q, 1H), 7.58 (t, 1H), 8.54 (q, 1H), 10.66 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 7.14 (m, 4H), 7.28 (d, 1H), 7.34 (m, 2H),
7.43 (m ,1H), 7.53 (q, 1H), 7.63 (m, 1H), 8.61 (q, 1H), 10.33 (s, 1H)
34:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.68 (s, 3H), 7.02 (m, 1H), 7.12 (m, 1H),
7.23 (t, 2H), 7.35 (m, 5H), 7.51 (d, 1H), 7.65 (t, 1H), 8.67 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 7.18 (m, 4H), 7.30 (q, 4H), 7.40 (t, 1H), 7.56
(d, 1H), 7.69 (d, 1H), 8.48 (s, 1H)
35:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.67 (s, 3H), 7.12 (m, 2H), 7.23 (m, 5H)
7.31 (t, 1H), 7.37 (m, 2H), 7.50 (s, 1H), 7.55 (d, 1H), 7.66 (t, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 7.13 (q, 1H), 7.21 (q, 3H), 7.27 (t, 2H), 7.33
(m, 2H), 7.43 (m, 3H), 7.54 (t, 1H), 8.02 (s, 1H), 10.29 (s, 1H), 12,49 (s, 1H)
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36:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.64 (s, 3H), 7.19 (s, 4H),
7.36 (t, 2H), 7.49 (m, 1H), 7.79 (d, 1H)
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.26 (s, 3H), 7.04(d, 2H), 7.13 (t, 2H),
7.25(m, 2H), 7.42 (m, 1H), 7.81 (m, 1H), 10.55 (s, 1H)
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 2.01 (s, 3H), 2.19 (s, 3H), 3.69 (s, 3H),
7.01 (m, 4H), 7.24 (m, 3H), 7.36 (q, 1H), 7.59 (d, 1H), 7.65 (d, 1H), 8.94 (s, 1H)
Final product: 1H NMR (600 MHz, CDCl3)δ 2.355 (s, 3H), 7.19 (m, 4H), 7.37 (m, 3H),
7.45 (m, 4H), 7.54 (m, 1H), 7.81 (m, 2H), 8.93 (s, 1H)
37:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.63 (s, 3H), 3.81 (s, 3H), 6.91 (d, 2H),
7.28 (d, 1H), 7.34 (t, 2H), 7.62 (t, 1H), 7.76 (m, 2H)
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ3.84 (s, 3H), 6.93 (t, 2H), 7.28 (q, 2H), 7.38
(q, 2H), 7.54 (m, 1H), 7.92 (t, 1H)
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 3.61 (s, 3H), 3.66 (s, 3H), 6.67 (d, 2H),
6.93 (t, 1H), 7.33 (m, 6H), 7.59 (d, 1H), 7.77 (d, 1H), 8.63 (d, 1H), 10.77 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 3.58 (s, 3H), 6.68 (d, 2H), 6.96 (m, 1H),
7.11 (s, 1H), 7.20 (d, 2H), 7.29 (m, 2H), 7.37 (m, 1H), 7.46 (t, 1H), 7.59 (t, 1H), 7.86 (q,
1H), 8.67 (d, 1H), 10.51 (s, 1H)
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38:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.24 (s, 3H), 3.74 (s, 3H), 7.09 (q, 1H),
7.24 (m, 1H), 7.34 (m, 3H), 7.44 (t, 1H), 7.52 (q, 2H), 7.64 (m, 1H), 7.71 (q, 1H), 7.84 (m,
1H), 8.12 (t, 1H), 10.01 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 2.27 (s, 3H), 7.14 (t, 1H), 7.23 (t, 1H), 7.34
(t, 3H), 7.46 (t, 1H), 7.54 (t, 1H), 7.61 (d, 2H), 7.72 (d, 1H), 7.78 (d, 1H), 8.15 (s, 1H),
9.90 (s, 1H), 12.69 (s, 1H)
39:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.72 (s, 3H), 3.75 (s, 3H), 7.09 (m, 1H),
7.43 (m, 3H), 7.52 (t, 2H), 7.63 (q, 4H), 7.77 (d, 1H), 7.86 (q, 3H), 8.13 (t, 1H), 9.87 (s,
1H)
Final product: 1H NMR (600 MHz, CDCl3)δ 7.41 (m, 3H), 7.58 (m, 3H), 7.81 (d, 1H),
7.88 (m, 2H), 7.94 (d, 1H), 8.00 (d, 1H), 8.11 (m, 2H), 8.37 (t, 2H), 9.88 (s, 1H)
40:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.00 (s, 3H), 3.71 (s, 3H), 6.98 (t, 1H), 7.21
(m, 3H), 7.27 (q, 1H), 7.34 (m, 4H), 7.57 (q, 1H), 7.66 (q, 1H), 8.93 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ 2.02 (s, 3H), 7.02 (t, 1H), 7.18 (m, 3H), 7.27
(t, 3H), 7.32 (d, 2H), 7.38 (q, 1H), 7.66 (t, 2H), 8.71 (s, 1H)
41:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.62 (s, 3H), 6.59 (m, 1H), 7.38 (m, 7H),
7.61 (d, 1H), 7.81 (q, 1H), 8.46 (d, 1H), 11.02 (s, 1H)
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Final product: 1H NMR (400 MHz, CDCl3)δ 6.72 (m, 1H), 7.19 (m, 5H), 7.36 (m ,2H),
7.44 (m, 2H), 7.54 (m, 1H), 7.71 (q, 1H), 7.95 (q, 1H), 8.60 (q, 1H), 10.73 (s, 1H)
42:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.92 (d, 3H), 7.24 (d, 2H),
7.51 (q, 2H), 7.68 (d, 2H), 8.10 (t, 2H)
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.36 (s, 3H), 3.96 (s, 3H), 7.24 (m, 3H),
7.49 (d, 3H), 7.70 (m, 3H), 8.01 (d, 2H), 8.88 (q, 1H), 11.89 (s, 1H)
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 2.36 (s, 4H), 7.28 (d, 2H), 7.56 (m, 1H),
7.67 (d, 2H), 7.77 (q, 1H), 7.88 (d, 2H), 8.04 (d, 2H), 8.72 (q, 1H), 11.83 (s, 1H)
43:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.64 (s, 3H), 7.19 (s, 4H),
7.36 (t, 2H), 7.49 (m, 1H), 7.79 (d, 1H)
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.26 (s, 3H), 7.04(d, 2H), 7.13 (t, 2H),
7.25(m, 2H), 7.42 (m, 1H), 7.81 (m, 1H), 10.55 (s, 1H)
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.65 (s, 3H), 3.62 (s, 3H), 6.92 (d, 2H), 7.02
(m, 3H), 7.14 (m, 4H), 7.24 (m, 3H), 7.33 (m, 1H), 7.41 (q, 1H), 7.51 (d, 1H), 7.79 (s,
1H), 8.51 (q, 1H), 10.66 (s, 1H)
Final product: 1H NMR (400 MHz, MeOD)δ 2.30 (s, 3H), 7.15 (d, 2H), 7.32 (m, 3H),
7.50 (t, 2H), 7.60 (t, 1H), 7.68 (q, 1H), 8.63 (q, 1H)
44:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.62 (s, 3H), 3.68 (s, 3H), 6.95 (m, 3H),
7.22 (d, 1H), 7.37 (m, 1H), 7.63 (m, 1H), 7.85 (q, 1H)
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Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 3.55 (s, 3H), 6.72 (d, 1H), 6.89 (q, 1H),
6.98 (d, 2H), 7.11 (t, 1H), 7.18 (m, 2H), 7.29 (m ,3H), 7.41 (q, 1H), 7.78 (q, 1H)
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 2.97 (s, 3H), 3.59 (s, 3H), 3.82 (s, 3H),
6.76 (d, 1H), 6.90 (q, 1H), 7.00 (m, 2H), 7.30 (m, 2H), 7.46 (q, 1H), 7.53 (m, 2H), 7.62 (q,
2H), 8.05 (s, 1H), 8.77 (q, 1H), 10.86 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3) 1.69 (s, 3H), 3.69 (s, 3H), 7.00 (t, 2H), 7.17
(m, 3H), 7.31 (m, 3H), 7.60 (m, 2H), 9.52 (s, 1H)
45:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ2.41 (s, 3H), 3.94 (s, 3H), 7.27 (t, 1H), 7.48
(d, 1H), 7.52 (d, 2H), 8.00 (q, 1H), 8.27 (d, 1H)
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.19 (s, 3H), 7.13 (d, 2H), 7.42 (t, 3H), 7.73
(t, 2H), 7.99 (s, 1H)
C NMR (400 MHz, D2O)δ167.7, 140.87, 136.80, 131.87, 131.34, 130.18, 129.79,
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128.43, 127.47, 127.06, 21.13
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.42 (s, 3H), 3.96 (s, 3H), 7.28 (d, 2H), 7.34
(m, 1H), 7.57 (t, 3H), 7.75 (m, 2H), 7.97 (t, 1H), 8.92 (q, 1H), 11.96 (s, 1H)
Final product: 1H NMR (400 MHz, CDCl3)δ2.34 (s, 3H), 7.26 (s, 2H), 7.42(s, 1H), 7.57
(s, 3H), 7.81, 7.90 (d, 3H), 8.21 (s, 1H), 8.95 (s, 1H), 12.16 (s, 1H)
46:
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.79 (s, 3H), 6.99 (m ,1H), 7.25 (m, 2H),
7.54 (m, 2H), 7.65 (m, 1H), 7.76 (m, 1H), 7.86 (m, 1H), 7.94 (q, 1H), 8.00 (m, 1H), 8.14
(t, 1H), 8.23 (t, 1H), 8.77 (q, 1H), 12.07 (s, 1H)
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Final product: 1H NMR (400 MHz, CDCl3)δ 7.11 (m ,1H), 7.34 (m ,1H), 7.43 (q, 2H),
7.54 (t, 1H), 7.65 (m, 3H), 7.76 (m, 1H), 7.98 (m, 1H), 8.12 (q, 1H), 8.22 (t, 1H), 8.90 (q,
1H), 11.96 (s, 1H)

2.17. Antibodies
KDM4B: AbCam, Cat# ab191434
KDM4E: Novus, Cat# NBP2-49124
H3K9me3: Abcam, Cat# ab176916
H3K4me: Active Motif, Cat# 39297
H3K4me2: Abcam, Cat# ab32356
GAPDH: Abgent, Cat# AP7873b
Goat anti-rabbit: Vectorlabs, Cat# BA-1000
Fluorescent secondaries:
Goat anti-rabbit: AbCam, Cat# ab150078
2.18. Primers
TaqMan® Gene Expression Assay Primers (ThermoFisher)
GAPDH: Mm99999915_g1
IL-6: Mm00446190_m1
TNF-α: Mm00443258_m1
IL-10: Mm01288386_m1
KDM4B: Mm01236310_m1
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IL-1b: Mm00434228_m1
Era: Mm00469669_m1

Chapter Three: Inhibition of the Histone Demethylase KDM4B Leads to Activation
of KDM1A, Attenuates Bacterial-Induced Pro-Inflammatory Cytokine Release and
Reduces Osteoclastogenesis.
3.1. Rationale and Hypothesis
Periodontal disease (PD) causes irreversible tissue damage and bone loss and
affects 46% of adult Americans. PD is a common chronic inflammatory disease
characterized by destruction of the supporting structures of the teeth.50, 186 This chapter
describes a novel approach that targets epigenetic control of gene expression in the host
to resolve the pro-inflammatory immune response driving PD.
The pro-inflammatory cytokines TNF-α and IL-6 are classically upregulated in
gingival connective tissues of PD patients, 36 and these cytokines are secreted from periopathogen activated macrophages through toll like receptor (TLR) signaling.225 TLR4
binding by periopathogenic LPS activates a signaling cascade that drives both cytokine
and chemokine production. KDM4B and its major substrate, H3K9, have been linked to
this process by several research groups.

157-159, 192

Because of this, we hypothesize that

KDM4B is a mediator of PD progression, and demonstrate that its demethylation activity
is a signature of several pro-inflammatory processes.
It is well known that histone demethylase enzymes are conserved throughout
species, and that these enzymes are commonly redundant, share substrate specificity

63

among different classes and families, and are coordinated in their activity. Multiple studies
support the idea that H3K4 and H3K9 methylation are mutually exclusive states.184, 226 For
example, cross talk between KDM4B and KDM1A enzymes leads to a balanced system
wherein lysine 9 methylation serves as a prerequisite to lysine 4 demethylation by
KDM1A.184 Because it is known that the demethylation activity of KDM1A on Histone 3
lysine 4 leads to repression of pro-inflammatory cytokine gene transcription,183 we
postulate that KDM4B is a positive regulator of the pro-inflammatory cytokine response
through an indirect mechanism by inhibiting KDM1A.
The current study aims to interrogate the activity of KDM4B as it relates to the
immune response in periodontal disease through the use of the JMJD2 demethylase
inhibitor ML324.212 We hypothesize that KDM4B inhibition using this inhibitor will result in
a reduced immune response to bacterial LPS, and that ML324 could prove useful as a
chemical tool and lead compound for future studies on PD or other hyper-inflammatory or
autoimmune diseases.
3.2. Results
3.2.a. KDM4B and KDM4E protein abundance is increased in areas of periodontal
inflammatory infiltrate.
To test the hypothesis that KDM4B is overexpressed upon LPS stimulation,
histological sections from the calvariae of mice that had been injected daily for 5 days with
fixed Aggregatibacter actinomycetemcomitans (A.a) or PBS were stained for KDM4B
protein. An increase in resorption pits due to osteoclast activity was observed in calvariae
treated with A.a, confirming this as a viable model for periodontal disease.217 Staining for
tartrate resistant acid phosphatase (TRAP) and F4/80 marked the area in the calvarial
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sections most active with inflammatory
infiltration. This region of interest showed a
significantly higher concentration of KDM4B
protein

(Figure

3.1A),

indicating

that

KDM4B protein levels correlate with immune
activation

in

periodontal

disease.

The

experimental inhibitor ML324 has also been
shown to inhibit the related demethylase
KDM4E,212 but this protein is not found in
mice.

Therefore,

tissue

sections

from

periodontally diseased human patients and
healthy controls were stained for both
KDM4E

and

immunohistochemistry.

KDM4B
The

using
connective

tissue underlying the oral epithelium was
chosen as the region of interest for analysis.
Figure 3.1. KDM4B abundance is significantly increased
in periodontal diseased versus healthy tissues. Live A.a
was injected subcutaneously into 12-week old C57BL/6 mice
at the mid-sagittal region of the calvarium every day for 5d.
Paraffin embedded sections were stained for F4/80, TRAP
and KDM4B using immunohistochemistry, all of which were
significantly upregulated in diseased versus healthy
calvariae. 10x Images presented are representative of the
data set. (A) In clinical periodontal specimens, the region of
interest was defined as the connective tissue underlying the
oral epithelium. Paraffin embedded sections were stained for
KDM4E and KDM4B using immunohistochemistry, both of
which were upregulated in diseased versus healthy patient
tissues. 20x images are representative of the data set. (B)
positive pixels quantified using color thresholding in ImageJ.
Data are presented as mean ± SD. Significance was
determined using a one-tailed Wilcoxon ranked sum test.
Epithelium (E) Calvarial Bone (C) Brain (B) *p<0.05,
***p<0.001. Scale bars, 100 μm

A statistically significant increase in both
KDM4B

and

KDM4E

abundance

was

observed in diseased versus healthy tissues
(Figure 3.1B), demonstrating that KDM4
enzymes are implicated in periodontal
disease status.
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3.2.b. ML324, previously defined as a KDM4E inhibitor, shows inhibitory
activity against KDM4B.
ML324 was docked into the active site of the KDM4A-E family in flexible mode, and was
found to have high computational selectivity for the KDM4B active site (Figure 3.2A).
ML324 exhibited a lower average binding energy to the KDM4B active site (-53.04
kcal/mol) for the top 30 conformers versus KDM4E (-42.52 kcal/mol). Additionally, we used
an Alphascreen® assay to determine the effect of ML324 on the demethylation activity of
KDM4B. Here we show that ML324 has inhibitory activity towards KDM4B, with an IC50
value of 4.9 μM (Figure 3.2B). Additionally, we have defined the EC50 of ML324 for
translational immunosuppression in primary macrophages to be 31 μM (Figure 3.2C). IL6 production drives periodontal disease pathogenesis, therefore the ability of ML324 to
effectively reduce the production of this cytokine emphasizes the potential of KDM4B
inhibitors as therapeutics for PD treatment.
3.2.c. KDM4B inhibition using ML324 results in a significantly reduced cytokine
immune response to Aa-LPS in macrophages.
After a 1-hour pre-tr eatment with ML324 (50 μM) followed by an inflammatory Aa-LPS
challenge (100 ng/mL), ELISA and PCR analysis revealed that the KDM4B inhibitor
ML324 significantly reduced the levels of inflammatory cytokines in primary murine
macrophages (Figure 3.3A-D). At 8- and 24-hour time points and in both male and female
cells, ML324 was able to significantly reduce IL-6 and TNF-α transcription and translation
compared to LPS treatment with vehicle control (DMSO). A pan-selective KDM4 family
inhibitor, JIB-04, was also able to produce this effect in most groups, but with a more
variable response. As expected, GSK-LSD1, a KDM1A inhibitor, produced either no
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change or a significant increase compared to
vehicle controls in the majority of groups. These
data

demonstrate

inhibition

reduces

not

only

that

inflammatory

KDM4B
cytokine

production but also that this effect is specific to
KDM4B over the KDM4 family as a whole. It is
important to note, however, that

enzyme

kinetics and mode of binding of ML324 to
KDM4B have not been described, although the
in vivo pharmacokinetics and ADME properties
of this compound are extremely favorable.212
Additionally,

this

data

shows

that

as

hypothesized, the activity of KDM4B and
KDM1A are negatively correlated; and that
inhibiting KDM1A via GSK-LSD1 gives an
opposing

effect on inflammatory cytokine

production compared to KDM4B inhibition using
ML324.

Figure 3.2. ML324 demonstrates inhibitory
activity towards KDM4B and causes dose
dependent immunosuppression. The KDM4A-E
protein crystal structures were subjected to
unbiased docking of ML324 where the top 30
conformers in the active site were used for
analysis (A). KDM4A and C had no poses of
ML324 dock into the active site of these enzymes,
therefore this data is not displayed. Inhibition of
KDM4B was assessed using an 11-point IC50
determination using the histone demethylase
AlphaScreen (PerkinElmer) assay in triplicate
resulting in an IC50 of 4.9 μM (B). The EC50 for
immunosuppression using ML324 was determined
to be 31 μM by measuring supernatant IL-6 protein
following a 24h Aa-LPS stimulation with variable
concentrations of ML324 in primary BMDM cells
(C). Cells were treated for 1h with each indicated
concentration of ML324, followed by Aa-LPS
challenge for 24h. The data were normalized as a
percentage of the maximal IL-6 response in
response to LPS. Data for all panels are
represented as mean ± SD. N=4

67

3.2.d. KDM4B inhibition using ML324 results in a significant reduction in
osteoclastogenesis.
After 5 days of priming bone marrow-derived hematopoietic stem cells into pre-osteoclasts
using macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear
factor kappa β ligand (RANK-L), osteoclastogenesis was significantly increased in cells
treated with RANK-L or Aa-LPS for 3 days compared to PBS treated cells, and this effect
was lost in cells pre-treated with ML324 (10 μM). TRAP+, multinucleated cells were
significantly increased in both cells treated with Aa-LPS as well as RANK-L compared to
PBS treated control cells. By contrast, in cells that were pre-treated with ML324, there was
C

D

Figure 3.3. KDM4B inhibition significantly reduces the A.a LPS-induced immune response in primary
macrophages. Male (A) and female (B) murine bone marrow derived macrophages were pre-treated for 1h with the
selective KDM4B inhibitor, ML324, a family-wide KDM4 inhibitor, JIB-04, and a KDM1A inhibitor, GSK-LSD1 or DMSO
vehicle. Following drug treatment, cells were challenged with Aa-LPS for 8 and 24h, where gene expression and
supernatant protein concentration were measured via rt-qPCR relative to GAPDH and ELISA relative to a standard
curve. Data was normalized as a percentage of the maximal response (red) in each group for display. (C,D). N=4 per
experiment, data is representative of 3 experiments. Data are presented as mean ± SD. Statistical significance was
determined using a repeated measures ANOVA with multiple comparisons. ***p<0.001, **p<0.01, *p<0.05 compared to
same sex LPS controls. N=4 per experiment, data is representative of 3 experiments.

no significant difference in osteoclast formation compared to control groups, regardless of
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whether cells were stimulated with Aa-LPS or RANK-L. Additionally, formed osteoclasts
appeared smaller, and had less intense TRAP staining (Figure 3.4).
3.2.e. Immunosuppressive effects of KDM4B inhibition act indirectly, through
demethylation of H3K4 by KDM1A.
To understand the mechanism for KDM4B inhibition induced immunosuppression, we
used the RAW264.7 macrophage cell line, which is the best representation of primary

C

Figure 3.4. KDM4B inhibition via ML324 prevents osteoclast formation induced by either A.a LPS or RANK-L.
Murine bone marrow was differentiated into osteoclasts by supplementation of the hematopoietic compartment with
M-CSF for 3 days and RANK-L + M-CSF for 2 days, where cells were rinsed and pre-treated for 1h with M-CSF and
ML324 or DMSO vehicle followed by supplementation with RANK-L or A.a LPS. After 72 hours, cells were fixed and
stained for tartrate resistant acid phosphatase. 3 representative images were taken of each well, and TRAP+,
multinucleated cells were counted in each field. 10x representative images of M1 and F2 are displayed. (A) Each
mouse (M1, M2 = male; F1, F2 = female) independently showed a significant increase in osteoclast formation in
response to LPS or RANK-L alone compared to PBS controls, but no significant difference in osteoclast formation
was observed between PBS and ML324 + LPS or ML324 + RANK-L treated cells (B). Male cells exhibit increased
osteoclastogenesis in response to RANK-L or A.a LPS compared to female cells. (C) Data is presented as the mean
number of osteoclasts in each field ± SD. Statistical significance was determined using a paired Friedman test or
two-way ANOVA with multiple comparisons at an α = 0.05. *p<0.05, **p<0.01 n = 3 fields per well, 2 wells per group,
per mouse.

bone marrow derived macrophages.227 Interestingly, when cycloheximide (5 μg/mL) was
co-administered with ML324 (50 μM) prior to Aa-LPS challenge in these cells, the ability
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of ML324 to reduce LPS-induced cytokine production is lost (Figure 3.5A). Because
cycloheximide
inhibits

eukaryotic

translation, this data
indicates that ML324induced
immunosuppression
relies on new protein
synthesis, and that
the reduced cytokine
response to LPS is
C

not a direct effect of
KDM4B inhibition, but
rather

requires
intracellular

signaling.

Figure 3.5. KDM4B inhibition mediated immunosuppressive effect is indirect,
requiring new protein synthesis and increased KDM1A activity. New protein
synthesis is required for the immunosuppressive effects of ML324 on the LPS-induced
immune response (A). Cells were pre-treated with cycloheximide (5ug/mL) for 4 h with
or without ML324 (50 μM) followed by Aa-LPS challenge (100ng/mL) for 16h where
RNA was collected and analyzed using qRT-PCR to measure IL-6 expression
compared to GAPDH as an endogenous control. Statistical significance was
determined using a repeated measures ANOVA with multiple comparisons.
Demethylation at H3K4 is significantly decreased in cells following LPS treatment, but
the effect is reversed upon addition of ML324. (B) ML324 treatment causes a
significant increase in H3K9me3 but not KDM4B, and these marks are not affected by
LPS treatment alone. (C) RAW264.7 cells were pre-treated for 1h with ML324 followed
by Aa-LPS challenge for 24h where H3K4 mono-methylation was measured in fixed
cells using immunofluorescent antibody to H3K4me at 10x. KDM1A activity is
significantly decreased following Aa-LPS treatment alone, but in combination with
ML324 pretreatment, KDM1A activity is increased. n = 3 wells, 48 fields/well, **p<0.01.
Data are represented as mean ± SD. Statistical significance was determined using
one-way ANOVA with multiple comparisons where the outcome was log transformed.

To determine if the
cellular response to
LPS altered KDM4B
expression levels, we
used a bioinformatics
database
Gene

(NCBI
Expression
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Figure 3.7. KDM4B inhibition reduces A.a.-induced inflammation in vitro and modifies calvarial bone loss
pattern in vivo. ML324 reduced fixed A.a induced inflammatory cytokine production in bone marrow derived
macrophages. (A) 12-week old C57BL/6 were injected subcutaneously and supraperiosteally at the mid-sagittal suture
daily for 5d with either A.a alone, A.a + drug or DMSO as a negative control. Mice were sacrificed on day 6, where
calvarial tissue was homogenized and protein isolated for western blot analysis of H3K9me3 compared to GAPDH as
internal control. (B) Calvarial bones were dissected and micro-computed tomography was run using a Scanco40
instrument at a 15μm resolution.(C) A region of interest was defined as a 150 mm3 cylinder centered at the bregma
point (intersection of the frontal and parietal bones at the midline). Total bone volume at this area was quantified using
AnalyzePro software. (D) Significance was determined using one-way ANOVA with multiple comparisons.

Omnibus (GEO) profiles). There was no change in mRNA expression of KDM4B in
response to LPS, suggesting that the activity of KDM4B as opposed to its expression level
drives the immune response to LPS. Further, KDM4A, KDM4C, and KDM4D also show
no significant differences in expression in response to LPS. To confirm that the activity of
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KDM4B was altered in response to LPS, the histone methylation marks H3K4me and
H3K9me3 were monitored by immunofluorescence following ML324 pre-treatment (50
μM) and Aa-LPS challenge. Concurrent with the absence of change in mRNA levels of
KDM4B, there was no significant difference in KDM4B protein levels between groups
(Figure 3.6). In contrast, the activity of KDM4B was decreased following ML324 pretreatment as evidenced by a significant increase in H3K9me3. Interestingly, there was not
a significant difference between control and LPS treated cells (Figure 3.5B). Conversely,
H3K4me levels significantly decreased following A.a.LPS challenge, but ML324 pretreatment not only reversed this effect, but caused a significant increase in H3K4me levels
compared to PBS controls (Figure 3.5B). These data together suggest that H3K4
methylation is differentially regulated by inflammatory stimuli in macrophages, and this
activity can be modulated indirectly through pharmacological inhibition of KDM4B.
3.2.f. KDM4B inhibition using ML324 and Experimental Inhibitor 36 Results in
Altered A.a-Induced Bone Loss
Phenotype
To recapitulate the anti-inflammatory
effects of ML324 treatment in vitro,
we used a 5-day

murine calvarial

model of periodontal disease using
Aggregatibacter
Figure 3.6. KDM4 family gene expression is unaltered in
response to LPS treatment. KDM4A-D mRNA expression in
primary bone marrow derived macrophages following
lipopolysaccharide stimulation for 24h. Data were obtained from
NCBI Gene Expression Omnibus profiles
(http://www.ncbi.nlm.nih.gov/geoprofiles; Reporter: GPL1261;
Record: GDS5196)

actinomycetemcomitans

induced

bone loss to probe the in vivo efficacy
of KDM4B inhibition. First, we verified
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Figure 3.8. ML324 alters macrophage polarization. KDM4B inhibition alters macrophage metabolism in response
to A.a LPS. Primary BMDMs were isolated and differentiated as previously described and were pre-treated with
ML324 at 50uM for 1 hour followed by A.a LPS (100ng/mL). 24 hours later, extracellular flux was analyzed using a
seahorse XFe96 instrument and following metabolic analysis, cells were incubated with phalloidin 488 and DAPI.
Representative images were acquired using the Hermes Wiscan system at 10x for morphological analysis. N=4.

that ML324 was able to reduce fixed A.a induced cytokine production, as all previous
experimentation was done using isolated LPS from A.a. We found that ML324 significantly
reduced A.a-induced inflammatory cytokine production to the same degree that it was
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previously shown to inhibit A.a LPS-induced inflammatory cytokine production. (Figure
3.7A) Mice were injected subcutaneously supraperiosteal to the calvarial bone with both
fixed whole A.a or PBS control and ML324, 36 or DMSO control for 5 days, and calvariae
and tissues overlying the calvarial bone were collected following sacrifice. We found that
in ML324 treated animals, H3K9me3 protein abundance was higher on average although
insignificant, suggesting the effect was on target and that KDM4B was indeed inhibited in
vivo. (Figure 3.7A) Unfortunately, we didn’t observe this effect with the experimental
inhibitor we tested, 36. This could be due to absorbance or metabolism issues, as neither
of these things were tested in our experimentation. Using micro-computed tomography,
we analyzed total bone volume for a specific region of interest that spans 10mm x 10mm
centered over the mid sagittal suture between the anterior and posterior calvarial bone.
(Figure 3.7C) Unfortunately, there was a highly variable and not robust enough response
to A.a treatment to discern any significant differences in our treatment groups. (Figure
3.7D) We did, however, observe a very consistently high average bone volume within our
region of interest for both ML324 and 36 treated animals. (Figure 3.7B) Overall, these
data suggest that KDM4B inhibition may serve as a useful therapeutic intervention for
prevention of periopathogen-induced bone resorption in vivo, but further experimentation
is needed.
3.2.g. ML324 alters A.a LPS-induced macrophage polarization
As previously mentioned, literature suggests that KDM4B may be involved in macrophage
polarization,46,

228-229

therefore

we

wanted

to

test

whether

ML324-induced

immunosuppression was due to M2 polarization or de-differentiation of macrophages.
Primary BMDMs were isolated and differentiated as previously described and were pre-
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treated with ML324 at 50 μM for 1 hour followed by A.a LPS (100ng/mL). 24 hours later,
mRNA was isolated and IL-10 expression was quantified using qRT-PCR and ML324 pretreated cells were found to have significantly higher IL-10 expression. (Figure 3.8A) To
determine if macrophages were M2 polarized, Extracellular flux was analyzed using a
seahorse XFe96 instrument as previously described.230 We found that LPS treated cells
are more glycolytic than PBS control cells, and ML324 pre-treatment rescued this effect.
(Figure 3.8B) Additionally, cells treated with LPS, with or without ML324 exhibit a reduced
spare respiratory capacity compared to PBS control treated cells. (Figure 3.8C) These
data suggest that ML324 pre-treatment alters macrophage metabolism with an overall
reduction in metabolic activity. To further probe macrophage polarization, we fluorescently
stained both the cytoplasm and nuclei of cells to visualize cell morphology, as clear
morphological differences are known to exist between M0 (un- or de- differentiated
macrophages), M1 (pro-inflammatory) or M2 (anti-inflammatory) macrophages.231 We
found that LPS treated macrophages exhibited an M1 phenotype, and ML324 pretreatment was able to rescue this effect, appearing very similar to PBS control treated
cells. (Figure 3.8D)
Chapter 4: Discovery of anti-periodontitis biphenyl-carboxamido-benzoic acids via
Phenotypic Screening Guided QSAR.
4.1. Rationale and Hypothesis
Previous data from the project laboratory implicates KDM4B as a regulatory
enzyme in periodontal disease progression through its role in suppressing both
osteoclastogenesis and inflammatory cytokine production in primary macrophages.232 The
exacerbated immune response of the periodontally diseased host is well known in the
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literature to be the source of the
tissue

damage

and

bone

loss

characteristic of the disease.50 Still,
therapeutic development has been
aimed towards local antimicrobials
such as chlorhexidine (PerioChip),
doxycycline

(Periostat)

and

minocycline (Arestin). Nevertheless,
these therapies provide a moderate

Figure 4.1. Compounds used to physicochemically cluster
screening data. Compounds 4,6 and 7 are previously published
KDM4B inhibitors. Compounds 8 is a KDM1A inhibitor.

clinical benefit at best,7 and require strict patient compliance with visits required as often
as every three months, which is rarely covered by insurance premiums. While the
microbial component of periodontal disease is indeed critical to disease pathogenesis,50,
64, 233

these therapies are applied by clinicians following standard of care treatment – which

is to remove plaque biofilms through scaling and root planning (SRP), effectively leaving
little to no microbial load immediately following treatment.233 Disease recurrence is driven
rather by a continuation of immune activation and an inability for the periodontal wounds
to heal.234-235 Given this information, one can imagine that a local immunosuppressive drug
would afford some benefit, allowing the host immune system to resolve, wounds to heal,
and ultimately preventing disease recurrence. The failure of previously explored antiinflammatory agents is likely due to their surface level targets such as secreted effector
proteins that do not cause heritable changes beyond single cell divisions. Epigenetic
therapeutics offer an advantage in this regard as they seek to reverse detrimental
environmental changes that have the ability to propagate harmful disease processes.
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In 2012, the NIH molecular libraries program reported the discovery of N-(3(dimethyamino)propyl-4-(8-hydroxyquinolin-6-yl)benzamide(1), a small molecule inhibitor
specifically targeting KDM4E.212 While this compound was shown to inhibit viral replication
of herpes simplex virus and cytomegalovirus, and later shown to induce depression in
mice at high doses,236 the compound was not probed for additional activity. We recently
reported that ML324, 8, is active toward a closely related enzyme, KDM4B, and has
immunosuppressive action in murine macrophages.232 While this compound exhibits good

A

B

C

D

Figure 4.2. Consensus orthogonal in silico docking strategy yielded novel and commercially available
immunosuppressive compounds. The public ZINC compound database was filtered and refined prior to docking to
increase computational efficiency as well as after docking to eliminate PAINS and false positives/negatives (A).
Compounds that ranked in the top 70% of both docks were physicochemically clustered and the cluster containing
ML324 and JIB-04 was sorted based on binding affinity(B). The top 8 compounds (C) were purchased from Vitas
laboratories. Compounds overlay space taken by natural ligands (D) 2-oxoglutarate (green), H3K9me3 (teal), KDM4B
(pink, PDB:4LXL), top 8 hits (orange), ML324 (red).

cell permeability, it is highly insoluble at effective doses and requires a 14-step synthesis
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for development of new derivatives.212 Because of this, we sought to determine novel
scaffolds with the potential to inhibit KDM4B, cause immunosuppressive effects, and
potentially serve as optimizable compounds for localized treatment of periodontal disease.
The current study utilized a multidisciplinary approach that combined consensus
computational docking data with phenotypic screens using primary murine macrophages
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Figure 4.3. Phenotypic screening data for compounds identified by in silico docking suggests compound 16 is
a promising hit for further development. Several initial hits caused suppressed the immune response to A.a LPS in
vitro. (A) n=2 Compound 16 was further evaluated for dose-dependent immunosuppression, N = 4 (B) as well as for
KDM4B inhibitory activity through measurement of H3K9me3 using fluorescent immunostaining, N = 3. (C,D) *p<0.05,
**p<0.01, ***p<0.001 compared to DMSO control via one-way ANOVA with multiple comparisons.
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to identify a derivatizable scaffold with KDM4B inhibitory action. We further used this
strategy to optimize our lead compounds and ultimately identified compound 46 as a
Table 4.1. Novel compounds synthesized.
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N
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potent immunosuppressive compound that could be used to treat periodontal disease
4.2. Results
4.2.a. Consensus computational docking followed by physicochemical clustering
yields commercially available immunosuppressive compounds

Scheme 4.1. Synthetic method for development of biphenyl carboxamido benzoic acids.

The ZINC database of molecules237 was filtered to retrieve compounds that were proposed
to have in vitro activity as well as compounds that could be purchased. This library was
further filtered to remove any potential pan-assay interference compounds (PAINS)238 as
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well as compounds with Lipinski violations, cytotoxic or unfavorable features239 (Figure
4.2A). The remaining compounds were subjected to high throughput screening for activity
towards the KDM4B active site using two separate software programs (DOCK6.5,
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Figure 4.4. Derivatives of 16 cause immunosuppression and were used to develop a binary QSAR model. The
phenotypic immunosuppressive screen data (A) was converted into binary data using statistical significance (P<0.05) as
a cutoff. A contingency analysis was run on the tested compounds to identify the physicochemical descriptors that were
most highly correlated with activity. The top 12 descriptors from this analysis were used (Table 4.2) to map a quantitative
structure activity relationship using Molecular Operating Environment software that had accuracy to predict actives of
100% and inactives of 100% (B). 30 compounds were predicted to have activity with >70% confidence, and this subset
included our current lead compound 42 (red). (C) *p<0.05, **p<0.01, ****p<0.0001 compared to DMSO control via oneway ANOVA with multiple comparisons.

Molecular Operating Environment). The consensus activity data240 was consolidated into
8,000 top compounds that were clustered based on similarity of their physicochemical
properties241 (Figure 4.2B) and the top compounds that were physicochemically similar to
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previously identified KDM4B inhibitors212,

242-243

were purchased for in vitro evaluation

(Figure 4.2C,D).
4.2.b.

2-([1,1'-biphenyl]-4-carboxamido)benzoic

acid

causes

dose-dependent

immunosuppression and increased H3K9me3
Several compounds from this initial clustered data set were active and suppressed
the immune response to A.a LPS at 50 μM (Figure 4.3A). We decided to move forward
with 11 because of its three membered structure and multiple routes of straight forward
combinatorial chemistry-based synthesis. Before investing significant time in development
of derivatives of 12, we confirmed a dose-dependent immunosuppressive response to A.a
LPS (Figure 4.3B) with a concurrent increase in H3K9me3 (4.3C, D), suggesting the effect
was on target.
4.2.c. Development of efficient synthetic methods for 2-([1,1'-biphenyl]-4carboxamido)benzoic acid derivatives
Sixteen derivates (Table 4.1; 13-28) were synthesized using a 5-step microwave
assisted synthesis from derivatized bromobenzenes, phenyltrifluorborates and 2-amino
benzoates (Scheme 4.1). Potential compounds were developed in silico, using
commercially available and economical starting materials. This library was docked to the
active site of KDM4B using consensus screening and hits were ranked based on binding
affinity. Top derivatives predicted by consensus scores as well as easy to synthesize
derivatives were synthesized. The first step of synthesis was a microwave assisted Suzuki
coupling of a bromobenzene and trifluoroborate to yield a two-ringed ester. The second

82

step was microwave-assisted saponification to cleave the ester into a reactive carboxylic
acid. The third step was further
Table 4.2. QSAR model descriptors and classes.

activated

the carbonyl

carbonyl

chloride

addition

of

an

into

followed

a
by

aminobenzoate

Physicochemical
Descriptor
balabanJ
BCUT_SLOGP_2
diameter

under basic conditions to yield the

GCUT_PEOE_1

final three-membered ester. The

VDistEq

radius

resulting ester was cleaved in the
final

step

using

the

same

Adjacency and distance
matrix

wienerPath
wienerPol
Kier2
Kier and Hall connectivity and
kappa shape

Kier3

microwave-assisted saponification

Descriptor Class

KierA3
PEOE_VSA+0

Partial charge

reaction to increase solubility of the
final compounds.
4.2.d.

2-([1,1'-biphenyl]-4-carboxamido)benzoic

acid

derivatives

prevent

inflammatory cytokine production in primary macrophages stimulated with A.a LPS
Derivatives were monitored for in vitro immunosuppressive activity using the
previously described periodontal disease inflammation model232 using primary murine
macrophages. 22, 24, 32 caused a significantly reduced secretion of the pro-inflammatory
cytokine, IL-6, in response to A.a LPS. (Figure 4.4A) resulting in an overall hit rate of 20%.
Compounds that significantly reduced inflammatory cytokine production compared to
DMSO controls as determined by one-way ANOVA with multiple comparisons were set as
actives while those that did not were set as inactives. These data were consolidated into
a binary quantitative structure activity relationship, where descriptors were chosen based
on contingency analysis (Table 4.2). Overall the model had an accuracy of 100% with a
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60% chance value. This model had an 100% accuracy to predict active hits with a 28%
chance value and a 100% accuracy to predict inactive compounds with a 72% chance
value (Figure 4.4B). The in silico library of derivatives was fit to this model and yielded 30
potential hits with greater than 70% chance of being active, one of which was one of our
current leads, compound 42. (Figure 4.4C) More importantly, several hits were eliminated
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Figure 4.5. Potent immunosuppressive compounds do not inhibit KDM4B in biochemical assays, but show
functional suppression of KDM4B activity in vitro. KDM4B activity was measured using an AlphaLISA® assay
with experimental inhibitors 44 and 46, exhibiting an IC50 >100 μM. (A) H3K9me3 (B) and H3K4me2 (C) protein
abundance was quantified in RAW264.7 macrophages 24h following A.a LPS challenge. Cells were fluorescently
stained and 36 images per well were captured using a Hermes Wiscan imaging system. Total fluorescence intensity
was normalized to cell number and statistical significance was determined using a one-way ANOVA with multiple
comparisons. N=3, 36 images per well. *p<0.05, **p<0.01, ***p<0.001.

from the pool of potential hits with high confidence.
4.2.e. A binary quantitative structure activity relationship guided synthesis of potent
immunosuppressors using phenotypic screening data
Our second generation (34-42) of inhibitors was synthesized (Table 4.1) and
compound 35, 38-40 and 42 significantly reduced the secretion of IL-6 in response to A.a
LPS in vitro. (Figure 4.4) The current lead compounds 44 and 46 were further evaluated
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because of their potent immunosuppressive action rivaling that of the control compound,
1. Surprisingly, using an AlphaLISA® KDM4B assay, we found that these compounds had
no inhibitory activity for KDM4B at concentrations as high as 100μM. (Figure 4.5A) On
the other hand, when we measured histone methylation marks as functional readouts in
response to inhibitor treatment in vitro, we found that 42 and 46 were able to significantly
increase H3K9me3 protein expression in vitro. (Figure 4.5B. D) Interestingly, while ML324
pre-treatment resulted in the expected decrease in H3K4me2, 16, 42 and 46 all caused a
significant increase in this mark. (Figure 4.5C, D) This suggests that these inhibitors may
target a similar enzyme with additional activity at H3K4me2 or may indirectly cause
inhibition of KDM4B through a process that is poorly recapitulated in biochemical assays
using recombinant protein.

Chapter 5: General Discussion and Future Directions:
5.1. General Discussion
To date, there is limited mechanistic data concerning the epigenetic modulation of
periodontal inflammation. A 2014 study by Meng et al. used a novel BET bromodomain
inhibitor, JQ1, in an experimental periodontal disease model and found that a decrease in
BRD4 recruitment led to a reduction in periodontal inflammation and subsequent bone
loss.244 Importantly, there have been no studies that suggest that any of the histone
demethylases play a direct role in the progression or persistence of periodontal disease,
despite the fact that numerous links between the KDM4 family of epigenetic modifiers and
inflammation have been published. The study described herein demonstrates that
inhibition of KDM4B reduces the pro-inflammatory cytokine immune response to bacterial
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lipopolysaccharide in macrophages. This effect occurs through new protein synthesis and
a subsequent overactivation of KDM1A. In the absence of KDM4B, macrophages do not
produce these inflammatory signals, and thus modulation of KDM4B activity could be
utilized to locally suppress the immune response to plaque and microbial biofilms in PD
patients for the resolution of inflammatory disease states.
To determine whether KDM4B inhibition could be used as a therapeutic strategy
to manage periodontal disease, we first demonstrated that the abundance of KDM4B
protein is significantly increased in areas of inflammatory infiltrate marked by increased
F4/80+ macrophage cells and increased tartrate resistant acid phosphatase (TRAP)+
osteoclastic cells following live A.a. subcutaneous injection into murine calvariae (Figure
3.1A).245 The murine genome does not express KDM4E,246 leading us to believe that the
ML324-induced immunomodulatory effect is entirely dependent on KDM4B. However, it is
likely that ML324 would also interact with KDM4E when administered in humans. Thus,
we sought to determine whether one or both of these enzymes were overproduced in
periopathogen-activated immune cells using human clinical PD tissues. Our results
demonstrate that the abundance of both KDM4B and KDM4E protein is significantly
increased in the oral epithelium of patients with periodontal disease, compared to healthy
controls. (Figure 3.1B).
Based on computational studies, ML324 demonstrated promising selectivity for
KDM4B (Figure 3.2A). Additionally, within the first 500 least energy docked poses, ML324
did not enter the active site of either KDM4A or KDM4C. ML324 is a methyl derivative of
the 8-hydroxyquinoline compounds developed as selective KDM4B inhibitors, yet thus far
the drug has only been published as an inhibitor of KDM4E with an IC50 of 920 nM. The
synthetic route used to produce JIB-04 is depicted in Scheme 3.1 and is described in
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detail in the Experimental section. Herein we show that ML324 has additional inhibitory
activity towards KDM4B, with an IC50 value of 4.9 μM (Figure 3.2B)247 and an EC50 value
for its immunosuppressive action in vitro of 31.0 μM (Figure 3.2C). JIB-04 is a pan Jumonji
domain demethylase inhibitor that inhibits KDM4B with an IC50 of 435 nM, but is a more
potent inhibitor of the related demethylases JARID1A and KDM4E. Another KDM4B
inhibitor, NSC636819, has been identified with a substantially higher IC50 against KDM4B
of 9.3 μM. These data identify ML324 as a potent inhibitor of KDM4B with moderate
selectivity that can be used as a tool to study phenotypic changes resulting from KDM4B
inhibition.
We thus reasoned that the periodontal immune response might be attenuated in
the absence of KDM4B activity. Macrophages have been established as the primary
mediator of the acute PD inflammatory response.248-250 For this reason, murine bone
marrow derived macrophages (BMDMs) have been utilized extensively to model oral
inflammatory responses. The pro-inflammatory cytokines TNF-α and IL-6 are classically
up regulated in gingival connective tissues of PD patients,

36

and these cytokines are

secreted from periopathogen activated macrophages through toll like receptor (TLR)
signaling.225 Lipopolysaccharide (LPS) is a predominate surface antigen that activates this
pathway;

251-252

therefore Aa-LPS, a well characterized periopathogen251-252 was used to

simulate the immune challenge present in PD. We anticipate that KDM4B inhibition will be
useful clinically following standard of care treatment (scaling and root planing (SRP)),
where cells are primed for responding to inflammatory stimuli but are temporarily halted
due to the elimination of the plaque biofilm. Introduction of an adjuvant therapy directly
after SRP allows for modulation of the host immune response that can prevent future
episodes of hyper-inflammation that drives tissue damage and bone loss. Since most
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patients resume building biofilms back almost immediately after clinical intervention, we
felt that a 1 hour pre-treatment would recapitulate the clinical setting most likely
encountered by PD patients. Our results show that ML324-induced inhibition of KDM4B
significantly suppresses the inflammatory response to bacterial LPS (Figure 3.3). TNF-α
mRNA at 8h after Aa-LPS challenge was the only time point tested that did not produce a
statistically significant effect, and this was consistent between both male and female cells
(Figure 3.3). This suggests that TNF-α and IL-6 are epigenetically regulated differently
due to the differences seen between groups in these cytokines.
An additional component of the pathogenesis of periodontal disease is the
imbalance in osteoimmunological mediators, resulting in a net loss of alveolar bone.
KDM4B was recently shown to drive mesenchymal stem cells towards an osteogenic
lineage preferentially over adipogenesis,253 but it is unknown how KDM4B regulates
osteoclastic cell types. Because we have seen a decrease in inflammatory mediators
required for endogenous osteoclastogenesis, we hypothesized that inhibition of KDM4B
would also reduce osteoclastogenesis. Our data demonstrates that osteoclastogenesis
proceeds normally with supplementation of either Aa-LPS or RANK-L, but when KDM4B
is inhibited in pre-osteoclasts using ML324, neither of these additives induce significant
osteoclast formation compared to vehicle control (Figure 3.4). This effect is seen in cells
from both sexes, although there is a significantly higher number of osteoclasts formed in
male cells compared to female cells, consistent with previous literature254 (Figure 3.4C).
The mechanism by which KDM4B inhibition promotes immunosuppression is
unknown. A study by Whetstine et al. demonstrated that KDM4B is structurally distinct
from its other family members, and has the lowest demethylase activity of the KDM4
family, for reasons that are not clear.255 KDM4B has also been recognized for its ability to
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demethylate non-histone proteins, many of which are transcriptional repressors.256 We
used the NCBI Gene Expression Omnibus databank to determine the differences in
expression of the KDM4 family of enzymes following lipopolysaccharide treatment in
primary BMDMs. We found that the expression level of these enzymes doesn’t reflect their
activity, as there are no significant differences in the expression of any KDM4 family gene
between LPS treated cells and vehicle treated cells (Figure 3.6). Therefore, we probed
methylation marks rather than expression of KDM4B itself to determine the mechanism of
action of ML324. The RAW264.7 macrophage cell line is the best representation of
primary bone marrow derived macrophages,227 but exhibit increased resiliency for use with
glass plates for fluorescent imaging and highly cytotoxic chemicals such as cycloheximide.
Herein we used immunofluorescent staining for methylation marks as well as
cycloheximide treatment to show that KDM4B-induced immunosuppression acts via an
indirect mechanism.257 After ML324 pre-treatment and Aa-LPS challenge in the presence
of cycloheximide, the immunosuppressive effects of ML324 are completely abolished
(Figure 3.5A). Additionally, it appears that when ML324 is added, even more IL-6 and
TNF-α are being transcribed in response to Aa-LPS (Figure 3.5A). We postulate that
because the cells are not able to effectively propagate intra- and inter-cellular signaling
events, the transcripts are aberrantly abundant. Although the immunosuppressive activity
of KDM4B inhibition requires new protein synthesis, an epigenetic mechanism is still at
play, as evidenced by the increase in H3K9me3 and H3K4me levels that are reversed
when KDM4B is inhibited (Figure 3.5B, C).
We were able to recapitulate our in vitro data in vivo using a murine calvarial model
of periodontal disease. The calvarial model used is superior to other methods to simulate
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PD: the ligature induced periodontal disease model is too acute for drug studies, while the
alveolar LPS injection model is not as robust and has unavoidable experimentalist
variability. Correlating with decreased osteoclastogenesis, we saw a decrease in bone
loss following A.a injection with both ML324 and E3ii treatment as well as an increase
between PBS vehicle and A.a treated mice. Tissues overlying the injection site were found
to have increased amounts of H3K9me3 in ML324 treated animals, but this wasn’t affected
by A.a injection alone, as was previously seen in vitro.
These data together demonstrate that newly synthesized protein signals KDM1A
following KDM4B inhibition, resulting in reduced transcriptional processing of proinflammatory cytokines as well as reduced osteoclast formation.

This translates to

reduced bone loss in vivo, which suggests that KDM4B inhibition could be a viable
therapeutic option for treating periodontal disease induced bone loss.
Drug discovery in the field of periodontics currently lacks momentum, and the
minimal drug discovery that does go on frequently recycles drugs used for other purposes
such as NSAIDs and antibiotics. We sought to utilize the well-established
interconnectedness of histone 3 lysine 9 methylation with the immune system to develop
drugs that could prevent the aberrant immune response that drives periodontal damage.
ML324 was originally published as a KDM4E inhibitor,212 and therefore exhibits
poor selectivity. This compound also suffers from extremely poor solubility. To enhance
both of these properties, we utilized an in silico docking approach to identify several hit
compounds for optimization. Our strategy utilized the consensus hits between multiple
docking algorithms within two different software programs (DOCK6.5 flexible dock and
Molecular Operating Environment rigid receptor dock) to eliminate potential false
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negatives. Prior to docking, we selected the ZINC library containing compounds with
predicted in vitro activity that were also available for sale. We filtered this compound library
by eliminating compounds that were not drug-like following Lipinski’s rules, had many
rotatable bonds and thus, had predicted cytotoxicity, and compounds that were not easy
to synthesize in a high throughput manner (Figure 4.1). This refined library was docked
into the active site of KDM4B and hits that ranked highly (>70th percentile) within both
programs were subjected to physicochemical clustering.220 We generated a set of
OpenBabel descriptors for each compound and clustered them based on similarity to
eachother as well as similarity to known KDM4B inhibitors (ML324212 1, JIB-04242 2 and
NSC636819243 3). We selected the smallest grouping that contained all three of these
inhibitors and made sure that this grouping did not contain the control compound, a
KDM1A inhibitor. (Figure 4.1)
We screened the purchased hits using a previously published232 periodontal
disease immunosuppression model using primary murine macrophages challenged with
Aggregatebacter actinomycetemcomitans lipopolysaccharide for 24 hours following 1 hour
pre-treatment at 50 μM with each compound. It is of critical importance in these
experiments to use primary cells from normal mice as KDM4B has been established as a
therapeutic target for anti-cancer agents.243, 258 Our experiments yielded several potential
hits from our initial screen of several different chemotypes including anti-anxiolytic
cinazepam259 13 and anti-tuberculosis drug aconiazide260 14. We ultimately selected 2([1,1'-biphenyl]-4-carboxamido)benzoic acid 16 due to its potency, solubility, ease of
derivatization as well as ease of overall synthesis. We divided the scaffold into three units,
each containing a benzene ring available for derivatization. We generated a combinatorial
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library in silico based on commercially available and economical starting materials. Our
initial library was subjected to consensus docking to prioritize our synthetic efforts. Despite
our awareness of the power in using this tool, we ultimately synthesized both compounds
with high binding affinity as well as compounds that we were able to synthesize efficiently.
For example, the parent scaffold (scaffold 1) had a simplified synthetic scheme because
of the purchasability of a two ringed starting material, eliminating the bulk of the synthetic
difficulty.
The Suzuki coupling reaction resulted in homocoupling of the bromobenzene
starting material, which had been previously reported.261 Additionally, the third step
sometimes generated an anyhydride product for selected diphenyl carboxylic acids. We
hypothesize that the nucleophilic amine starting material was stabilized by the carboxylic
acid hydroxy group, reducing its nucleophilicity and hydrophilicity making both the reaction
and purification extremely difficult. Because of this, several hits were synthesized based
on our ability to purchase starting materials that eliminated steps in our method (biphenyl
carboxylic acids 19, eliminating the Suzuki coupling and ester cleavage reactions) as well
as compounds that were very reactive or could be used in heavy excess due to the high
yield of the previous step.
Our synthetic method (Scheme 4.1) was relatively simple and utilized microwave assisted
reactions to reduce the total time for synthesis. Purification of the three-ringed product 22
from the amine starting material 21 proved unexpectedly difficult, likely due to strong
hydrogen bonding between the amine hydrogen and the lone pairs of the adjacent acetate
oxygen. For this reason, reactions were crystallized rather than purified by column
chromatography whenever possible. In the second step, we found that lyophilization of the
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starting material 21 as well as removing the excess oxalyl chloride prior to adding the
nucleophilic amine 21 were critical for the success of this step. To do this more efficiently,
we used dry DCE rather than DCM as was previously published,224 due to its higher boiling
point. At this point, all reactions were bright yellow in color. For the next step we pre-stirred
triethylamine with the amine 21, and this solution was added via cannula transfer to the
reaction under nitrogen. When using lower equivalents of TEA the reaction did not
proceed, likely due to strong hydrogen bonding between the amine hydrogen and the lone
pairs of the adjacent acetate oxygen which decreased the nucleophilicity of the amine.
When successful, the reaction proceeded almost instantaneously, with a sharp color
change and white gas occurring in almost every reaction. Unfortunately, the final step was
critical to the solubility of our final compounds. Thus, the ester 22 of each drug could not
be considered for in vitro testing due to poor solubility. Purity of our final compounds was
confirmed using UPLC, and compounds were characterized by NMR. Final compounds
were only utilized for biological evaluation if purity was >95% by UPLC.
We utilized the immunosuppressive action (Figure 4.4A) of the first 16 (16, 23-37)
compounds synthesized to build a quantitative structure activity relationship (Figure 4.4B)
utilizing 11 descriptors. We chose to use contingency analysis for selection of descriptors
so that our methodology would be reproducible. We had a 20% hit rate with a 100%
probability to predict negative hits but only a 88% probability to predict positive hits. This
model was used to guide synthesis of 9 more compounds (38-46), several of which
showed a significantly higher efficacy than the first series of inhibitors (Figure 4.4A), with
a hit rate within our second generation of 56% yielding an overall hit rate of 29%. We
tested our two final best compounds as predicted by docking, QSAR and phenotypic
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screening (44, 46) for KDM4B inhibitory action and surprisingly found that they exhibited
IC50 values >100 μM.
Conclusion
ML324 is an effective inhibitor of KDM4B, which acts through binding to KDM4B
and initiating de novo protein synthesis, subsequent KDM1A activation followed by H3K4
demethylation. This results in a reduced cytokine inflammatory response and decreased
osteoclastogenesis in primary bone marrow cells. These data together provide a novel
mechanism of immunomodulation through epigenetic modification, which can be used for
further development of therapeutics for treatment of hyper-inflammatory disorders such as
periodontal disease.
We were able to use high-throughput computational chemical consensus screens
coupled with in vitro phenotypic screening to identify novel compounds that cause
immunosuppression coupled to epigenetic changes. We optimized these with our
phenotypic screening data to identify multiple potent compounds. We conclude that novel
scaffolds have been identified that could serve useful in treating periodontal disease
through a unique epigenetic mechanism.
5.2. Future Directions
5.2.a. Further drug development
This dissertation describes the identification of a novel scaffold for immunosuppressive
drugs that could be used to treat hyper inflammatory disorders including periodontal
disease. Additionally, this dissertation validated KDM4B as an epigenetic enzyme that
produces immunosuppressive effects when inhibited in vitro and in vivo. Unfortunately,
the drug discovery strategy utilized in this dissertation did not combine these two aims –
94

and our immunosuppressive compounds do not work through inhibition of KDM4B. Further
drug discovery research should be conducted using enzymatic assay-based QSAR that
correlates IC50 with structural characteristics rather than phenotypic immunosuppression
which can be vague and off-target.
5.2.b. Human samples
While human tissues were stained immunohistochemically for KDM4B protein abundance
from periodontally diseased and healthy tissues in this dissertation, no further human data
was acquired. While there are obvious benefits associated with using a murine system to
study periodontal disease such as cost, simplicity, sentience and complete genetic control,
there are equally obvious limitations. For example, mice do not develop periodontal
disease and are not naturally colonized with periodontal pathogens such as
Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans. Because of this, it
would be more clinically relevant to measure the efficacy of KDM4B inhibition to cause
immunosuppression in human tissues or cells. Future studies should incorporate the use
of either an immortalized human cell line or even a human macrophage cancer cell line
such as KG-1 cells.
5.2.c. Assay development
As mentioned previously, the quantitative structure activity relationship that was
developed through completion of this dissertation is binary and is based on statistically
significant phenotypic immunosuppression data. While this type of screening produces
clinically applicable inhibitors, the potential for development of drugs that are off-target is
very high. This strategy was utilized due to the limited options available for biochemically
assaying the enzymatic activity of KDM4B. The main strategy used currently is an
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alphalisa or AlphaScreen assay which is costly and requires an advanced alpha count
reading plate reader. Future work should focus on development of a more economical
enzyme assay, or at the very least the growth of KDM4B protein in E. coli.
5.2.d. CRISPR/Cas9
While we feel confident that KDM4B inhibition presents a valid therapeutic strategy for
treatment of inflammatory diseases through the data presented within this dissertation,
genetic deletion of KDM4B would be a worthwhile endeavor in the multitude of cell types
involved in periodontal disease pathogenesis. As drug discovery toward KDM4B inhibitors
gains momentum and more potent inhibitors are developed, it is prudent to understand
the systemic effects of deletion of KDM4B in both health and disease states. Several
groups have successfully deleted KDM4B through the use of CRISPR/Cas9 technology,
but it has yet to be done in macrophages or in an inflammatory setting. These studies
would help determine whether KDM4B inhibition is feasible, the extent of compensatory
mechanisms among the KDM4 enzyme family, and potential positive or negative feedback
mechanisms that may come into play with long-term KDM4B inhibition therapy.
5.2.e. Macrophage polarization
Initial studies were conducted within this dissertation towards understanding the
polarization of macrophages following KDM4B inhibition. Unfortunately, these studies
were contradictory, and no definitive conclusions could be made. Macrophages treated
with KDM4B inhibitors secrete less pro-inflammatory cytokines, increased IL-10, an antiinflammatory cytokine, do not morphologically look like M1 macrophages when stimulated
with LPS, and have a metabolic profile consistent with depolarized M0 or M2
macrophages. Previous literature suggests that other KDM enzymes regulate
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macrophage polarization, therefore it is entirely possible that KDM4B is also involved in
this switch that is seen in periodontal disease pathogenesis. Future work should clearly
delineate whether KDM4B inhibition depolarizes or de-differentiates macrophages or if it
induces M2 macrophage polarization. This could be done using cell sorting experiments
or immunofluorescent staining of M1 and M2 macrophage markers.
5.2.f. Optimization and expansion of calvarial model
The in vivo experimentation conducted in this dissertation was unfortunately limited to
male mice only. This decision was made based on the lack of differences seen between
male and female cells in their inflammatory response to LPS and whole bacteria following
KDM4B inhibition. Differences were observed in osteoclastogenesis between male and
female cells in response to KDM4B inhibitors. These differences were seen with and
without KDM4B inhibition, and previous literature has described differences between male
and female osteoclastogenesis. While these facts validate the use of a single sex for
preliminary experimentation, testing should be done in both male and female mice prior to
translation to clinical studies.
Additionally, the A.a induced bone loss observed in our experimentation was not robust
enough to determine significant differences between groups. A pilot study should be
conducted that includes a dose-response to fixed A.a and experiments should be
repeated. The most potent immunosuppressor, compound 46, should also be tested in
vivo.
5.2.g. Additional Disease models
Because the general idea of KDM4B inhibitors as therapeutics for periodontal disease is
based on the concept of immunosuppression, it is conceivable that these compounds
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could be used for various additional hyper-inflammatory diseases. For example,
rheumatoid arthritis is a common degenerative disease driven by the immune response
and affects more than 21% of the adult American population and would thus present a
potential candidate disease that could be treated using KDM4B inhibitors. Additionally, as
mentioned previously, periodontal disease has been linked to even more prevalent
systemic diseases such as diabetes and obesity, for which an epigenetic mechanism
underlying their interconnectedness has not been explored. A challenge with treatment of
other diseases is the issue of systemic administration – in fact, the major appeal of
epigenetic therapy for periodontal disease is the ability to provide local treatment directly
in the oral cavity. Therefore, future work should focus on the potential effects of systemic
KDM4B inhibitor administration.
5.3. Impact on the field
This project has several important implications that will make a significant impact across
several fields, including periodontics, immunology and epigenetics. First, the regulation of
periodontal disease by the epigenetic histone demethylase KDM4B was entirely unknown
prior to completion of this dissertation. This project demonstrated that KDM4B plays a
regulatory role in both perio-pathogen induced inflammation as well as bone loss. Prior to
this study, host modulation therapy for treating periodontal disease through histone
demethylase inhibition has yet to be translated into a pre-clinical model of the disease.
This project resulted in a series of small molecule epigenetic modulating drugs and
ultimately these compounds were tested in vivo. The synthetic methodology described in
this dissertation has been optimized for development of additional inhibitors, to enable
extension of this compound library efficiently in future studies. In addition to the novel
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series of inhibitors that was developed, this project defined ML324 as a KDM4B inhibitor
for the first time and extended the therapeutic potential for this drug to include reduction
of inflammation and bone loss. Also, this project further confirmed the mutual exclusivity
of the epigenetic enzymes KDM1A and KDM4B. The epigenetic landscape is extremely
complex and yet to be completely understood; therefore, studies that elucidate interactions
between epigenetic mechanisms are critically important. Overall, this project was able to
bridge the gap in understanding between multiple fields.
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